Publications

G Steven Bova – PELICAN Personalized Cancer Medicine

2020-2024

1. Kiviaho, A, Eerola, SK, Kallio, HML, Andersen, MK, Hoikka, M, Tiihonen, AM et al.. Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. Nat Commun. 2024;15 (1):9949. doi: 10.1038/s41467-024-54364-1. PubMed PMID:39550375 PubMed Central PMC11569175.
2. Woodcock, DJ, Sahli, A, Teslo, R, Bhandari, V, Gruber, AJ, Ziubroniewicz, A et al.. Genomic evolution shapes prostate cancer disease type. Cell Genom. 2024;4 (3):100511. doi: 10.1016/j.xgen.2024.100511. PubMed PMID:38428419 PubMed Central PMC10943594.

Search PubMed

1. Kaljunen, H, Taavitsainen, S, Kaarijärvi, R, Takala, E, Paakinaho, V, Nykter, M et al.. Fanconi anemia pathway regulation by FANCI in prostate cancer. Front Oncol. 2023;13 :1260826. doi: 10.3389/fonc.2023.1260826. PubMed PMID:38023254 PubMed Central PMC10643534.
2. Nurminen, A, Jaatinen, S, Taavitsainen, S, Högnäs, G, Lesluyes, T, Ansari-Pour, N et al.. Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine. Genome Med. 2023;15 (1):82. doi: 10.1186/s13073-023-01242-y. PubMed PMID:37828555 PubMed Central PMC10571458.
3. Sattari, M, Kohvakka, A, Moradi, E, Rauhala, H, Urhonen, H, Isaacs, WB et al.. Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases. Endocr Relat Cancer. 2023;30 (8):. doi: 10.1530/ERC-22-0247. PubMed PMID:37140987 PubMed Central PMC10326635.
4. Yakneen, S, Waszak, SM, PCAWG Technical Working Group, Gertz, M, Korbel, JO, PCAWG Consortium et al.. Author Correction: Butler enables rapid cloud-based analysis of thousands of human genomes. Nat Biotechnol. 2023;41 (4):577. doi: 10.1038/s41587-022-01554-1. PubMed PMID:36944844 PubMed Central PMC10110458.
5. Rodriguez-Martin, B, Alvarez, EG, Baez-Ortega, A, Zamora, J, Supek, F, Demeulemeester, J et al.. Author Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet. 2023;55 (6):1080. doi: 10.1038/s41588-023-01319-9. PubMed PMID:36944736 PubMed Central PMC10260396.
6. Akdemir, KC, Le, VT, Chandran, S, Li, Y, Verhaak, RG, Beroukhim, R et al.. Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet. 2023;55 (6):1079. doi: 10.1038/s41588-023-01318-w. PubMed PMID:36944735 PubMed Central PMC10260394.
7. Zapatka, M, Borozan, I, Brewer, DS, Iskar, M, Grundhoff, A, Alawi, M et al.. Author Correction: The landscape of viral associations in human cancers. Nat Genet. 2023;55 (6):1077. doi: 10.1038/s41588-023-01316-y. PubMed PMID:36944734 PubMed Central PMC10260395.
8. Cortés-Ciriano, I, Lee, JJ, Xi, R, Jain, D, Jung, YL, Yang, L et al.. Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. 2023;55 (6):1076. doi: 10.1038/s41588-023-01315-z. PubMed PMID:36944733 PubMed Central PMC10260391.
9. Yuan, Y, Ju, YS, Kim, Y, Li, J, Wang, Y, Yoon, CJ et al.. Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet. 2023;55 (6):1078. doi: 10.1038/s41588-023-01317-x. PubMed PMID:36944732 PubMed Central PMC10260393.
10. Alexandrov, LB, Kim, J, Haradhvala, NJ, Huang, MN, Tian Ng, AW, Wu, Y et al.. Author Correction: The repertoire of mutational signatures in human cancer. Nature. 2023;614 (7948):E41. doi: 10.1038/s41586-022-05600-5. PubMed PMID:36697836 PubMed Central PMC9931578.
11. Li, Y, Roberts, ND, Wala, JA, Shapira, O, Schumacher, SE, Kumar, K et al.. Author Correction: Patterns of somatic structural variation in human cancer genomes. Nature. 2023;614 (7948):E38. doi: 10.1038/s41586-022-05597-x. PubMed PMID:36697835 PubMed Central PMC9931568.
12. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Author Correction: Pan-cancer analysis of whole genomes. Nature. 2023;614 (7948):E39. doi: 10.1038/s41586-022-05598-w. PubMed PMID:36697834 PubMed Central PMC9931570.
13. Gerstung, M, Jolly, C, Leshchiner, I, Dentro, SC, Gonzalez, S, Rosebrock, D et al.. Author Correction: The evolutionary history of 2,658 cancers. Nature. 2023;614 (7948):E42. doi: 10.1038/s41586-022-05601-4. PubMed PMID:36697833 PubMed Central PMC9931577.
14. Rheinbay, E, Nielsen, MM, Abascal, F, Wala, JA, Shapira, O, Tiao, G et al.. Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2023;614 (7948):E40. doi: 10.1038/s41586-022-05599-9. PubMed PMID:36697832 PubMed Central PMC9931557.
15. PCAWG Transcriptome Core Group, Calabrese, C, Davidson, NR, Demircioğlu, D, Fonseca, NA, He, Y et al.. Author Correction: Genomic basis for RNA alterations in cancer. Nature. 2023;614 (7948):E37. doi: 10.1038/s41586-022-05596-y. PubMed PMID:36697831 PubMed Central PMC9931574.

Search PubMed

1. Carlevaro-Fita, J, Lanzós, A, Feuerbach, L, Hong, C, Mas-Ponte, D, Pedersen, JS et al.. Author Correction: Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol. 2022;5 (1):1347. doi: 10.1038/s42003-022-03769-z. PubMed PMID:36482178 PubMed Central PMC9732278.
2. Rubanova, Y, Shi, R, Harrigan, CF, Li, R, Wintersinger, J, Sahin, N et al.. Author Correction: Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nat Commun. 2022;13 (1):7567. doi: 10.1038/s41467-022-32336-7. PubMed PMID:36482170 PubMed Central PMC9731941.
3. Sieverling, L, Hong, C, Koser, SD, Ginsbach, P, Kleinheinz, K, Hutter, B et al.. Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun. 2022;13 (1):7574. doi: 10.1038/s41467-022-32328-7. PubMed PMID:36481818 PubMed Central PMC9731961.
4. Shuai, S, PCAWG Drivers and Functional Interpretation Working Group, Gallinger, S, Stein, LD, PCAWG Consortium. Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nat Commun. 2022;13 (1):7571. doi: 10.1038/s41467-022-32343-8. PubMed PMID:36481739 PubMed Central PMC9732291.
5. Cmero, M, Yuan, K, Ong, CS, Schröder, J, PCAWG Evolution and Heterogeneity Working Group, Corcoran, NM et al.. Author Correction: Inferring structural variant cancer cell fraction. Nat Commun. 2022;13 (1):7568. doi: 10.1038/s41467-022-32338-5. PubMed PMID:36481724 PubMed Central PMC9732297.
6. Jiao, W, Atwal, G, Polak, P, Karlic, R, Cuppen, E, PCAWG Tumor Subtypes and Clinical Translation Working Group et al.. Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun. 2022;13 (1):7573. doi: 10.1038/s41467-022-32329-6. PubMed PMID:36481665 PubMed Central PMC9732335.
7. Paczkowska, M, Barenboim, J, Sintupisut, N, Fox, NS, Zhu, H, Abd-Rabbo, D et al.. Author Correction: Integrative pathway enrichment analysis of multivariate omics data. Nat Commun. 2022;13 (1):7570. doi: 10.1038/s41467-022-32342-9. PubMed PMID:36481658 PubMed Central PMC9731958.
8. Zhang, Y, Chen, F, Fonseca, NA, He, Y, Fujita, M, Nakagawa, H et al.. Author Correction: High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. Nat Commun. 2022;13 (1):7572. doi: 10.1038/s41467-022-32333-w. PubMed PMID:36481652 PubMed Central PMC9732340.
9. Bhandari, V, Li, CH, Bristow, RG, Boutros, PC, PCAWG Consortium. Author Correction: Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun. 2022;13 (1):7569. doi: 10.1038/s41467-022-32339-4. PubMed PMID:36481612 PubMed Central PMC9731962.
10. Reyna, MA, Haan, D, Paczkowska, M, Verbeke, LPC, Vazquez, M, Kahraman, A et al.. Author Correction: Pathway and network analysis of more than 2500 whole cancer genomes. Nat Commun. 2022;13 (1):7566. doi: 10.1038/s41467-022-32334-9. PubMed PMID:36481610 PubMed Central PMC9732045.
11. Buhigas, C, Warren, AY, Leung, WK, Whitaker, HC, Luxton, HJ, Hawkins, S et al.. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates. Mol Cancer. 2022;21 (1):183. doi: 10.1186/s12943-022-01644-3. PubMed PMID:36131292 PubMed Central PMC9494848.
12. Ouellet, V, Erickson, A, GAP1 UTMAs Contributing Investigators, Wiley, K, Morrissey, C, Berge, V et al.. The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource. Cancer Epidemiol Biomarkers Prev. 2022;31 (4):715-727. doi: 10.1158/1055-9965.EPI-21-0600. PubMed PMID:35131885 PubMed Central PMC9381093.

Search PubMed

1. Li, QK, Chen, J, Hu, Y, Höti, N, Lih, TM, Thomas, SN et al.. Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors. Sci Rep. 2021;11 (1):18936. doi: 10.1038/s41598-021-98410-0. PubMed PMID:34556748 PubMed Central PMC8460832.
2. Ketola, K, Kaljunen, H, Taavitsainen, S, Kaarijärvi, R, Järvelä, E, Rodríguez-Martín, B et al.. Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity. Cancer Res. 2021;81 (19):4901-4909. doi: 10.1158/0008-5472.CAN-21-0371. PubMed PMID:34348967 PubMed Central PMC9397610.
3. Jasu, J, Tolonen, T, Antonarakis, ES, Beltran, H, Halabi, S, Eisenberger, MA et al.. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. Eur Urol Open Sci. 2021;30 :47-62. doi: 10.1016/j.euros.2021.05.011. PubMed PMID:34337548 PubMed Central PMC8317817.
4. Valkonen, M, Hognas, G, Bova, GS, Ruusuvuori, P. Generalized Fixation Invariant Nuclei Detection Through Domain Adaptation Based Deep Learning. IEEE J Biomed Health Inform. 2021;25 (5):1747-1757. doi: 10.1109/JBHI.2020.3039414. PubMed PMID:33211668 .

Search PubMed

1. Bailey, MH, Meyerson, WU, Dursi, LJ, Wang, LB, Dong, G, Liang, WW et al.. Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun. 2020;11 (1):6232. doi: 10.1038/s41467-020-20128-w. PubMed PMID:33257764 PubMed Central PMC7705717.
2. Woodcock, DJ, Riabchenko, E, Taavitsainen, S, Kankainen, M, Gundem, G, Brewer, DS et al.. Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy. Nat Commun. 2020;11 (1):5070. doi: 10.1038/s41467-020-18843-5. PubMed PMID:33033260 PubMed Central PMC7545111.
3. Bailey, MH, Meyerson, WU, Dursi, LJ, Wang, LB, Dong, G, Liang, WW et al.. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun. 2020;11 (1):4748. doi: 10.1038/s41467-020-18151-y. PubMed PMID:32958763 PubMed Central PMC7505971.
4. Li, CH, Prokopec, SD, Sun, RX, Yousif, F, Schmitz, N, PCAWG Tumour Subtypes and Clinical Translation et al.. Sex differences in oncogenic mutational processes. Nat Commun. 2020;11 (1):4330. doi: 10.1038/s41467-020-17359-2. PubMed PMID:32859912 PubMed Central PMC7455744.
5. Gundem, G, Van Loo, P, Kremeyer, B, Alexandrov, LB, Tubio, JMC, Papaemmanuil, E et al.. Author Correction: The evolutionary history of lethal metastatic prostate cancer. Nature. 2020;584 (7820):E18. doi: 10.1038/s41586-020-2581-5. PubMed PMID:32728210 .
6. PCAWG Transcriptome Core Group, Calabrese, C, Davidson, NR, Demircioğlu, D, Fonseca, NA, He, Y et al.. Genomic basis for RNA alterations in cancer. Nature. 2020;578 (7793):129-136. doi: 10.1038/s41586-020-1970-0. PubMed PMID:32025019 PubMed Central PMC7054216.
7. Alexandrov, LB, Kim, J, Haradhvala, NJ, Huang, MN, Tian Ng, AW, Wu, Y et al.. The repertoire of mutational signatures in human cancer. Nature. 2020;578 (7793):94-101. doi: 10.1038/s41586-020-1943-3. PubMed PMID:32025018 PubMed Central PMC7054213.
8. Rheinbay, E, Nielsen, MM, Abascal, F, Wala, JA, Shapira, O, Tiao, G et al.. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020;578 (7793):102-111. doi: 10.1038/s41586-020-1965-x. PubMed PMID:32025015 PubMed Central PMC7054214.
9. Gerstung, M, Jolly, C, Leshchiner, I, Dentro, SC, Gonzalez, S, Rosebrock, D et al.. The evolutionary history of 2,658 cancers. Nature. 2020;578 (7793):122-128. doi: 10.1038/s41586-019-1907-7. PubMed PMID:32025013 PubMed Central PMC7054212.
10. Li, Y, Roberts, ND, Wala, JA, Shapira, O, Schumacher, SE, Kumar, K et al.. Patterns of somatic structural variation in human cancer genomes. Nature. 2020;578 (7793):112-121. doi: 10.1038/s41586-019-1913-9. PubMed PMID:32025012 PubMed Central PMC7025897.
11. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature. 2020;578 (7793):82-93. doi: 10.1038/s41586-020-1969-6. PubMed PMID:32025007 PubMed Central PMC7025898.
12. Cortés-Ciriano, I, Lee, JJ, Xi, R, Jain, D, Jung, YL, Yang, L et al.. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. 2020;52 (3):331-341. doi: 10.1038/s41588-019-0576-7. PubMed PMID:32025003 PubMed Central PMC7058534.
13. Zapatka, M, Borozan, I, Brewer, DS, Iskar, M, Grundhoff, A, Alawi, M et al.. The landscape of viral associations in human cancers. Nat Genet. 2020;52 (3):320-330. doi: 10.1038/s41588-019-0558-9. PubMed PMID:32025001 PubMed Central PMC8076016.
14. Akdemir, KC, Le, VT, Chandran, S, Li, Y, Verhaak, RG, Beroukhim, R et al.. Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet. 2020;52 (3):294-305. doi: 10.1038/s41588-019-0564-y. PubMed PMID:32024999 PubMed Central PMC7058537.
15. Rodriguez-Martin, B, Alvarez, EG, Baez-Ortega, A, Zamora, J, Supek, F, Demeulemeester, J et al.. Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet. 2020;52 (3):306-319. doi: 10.1038/s41588-019-0562-0. PubMed PMID:32024998 PubMed Central PMC7058536.
16. Yuan, Y, Ju, YS, Kim, Y, Li, J, Wang, Y, Yoon, CJ et al.. Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet. 2020;52 (3):342-352. doi: 10.1038/s41588-019-0557-x. PubMed PMID:32024997 PubMed Central PMC7058535.
17. Carlevaro-Fita, J, Lanzós, A, Feuerbach, L, Hong, C, Mas-Ponte, D, Pedersen, JS et al.. Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol. 2020;3 (1):56. doi: 10.1038/s42003-019-0741-7. PubMed PMID:32024996 PubMed Central PMC7002399.
18. Yakneen, S, Waszak, SM, PCAWG Technical Working Group, Gertz, M, Korbel, JO, PCAWG Consortium et al.. Butler enables rapid cloud-based analysis of thousands of human genomes. Nat Biotechnol. 2020;38 (3):288-292. doi: 10.1038/s41587-019-0360-3. PubMed PMID:32024987 PubMed Central PMC7062635.
19. Reyna, MA, Haan, D, Paczkowska, M, Verbeke, LPC, Vazquez, M, Kahraman, A et al.. Pathway and network analysis of more than 2500 whole cancer genomes. Nat Commun. 2020;11 (1):729. doi: 10.1038/s41467-020-14367-0. PubMed PMID:32024854 PubMed Central PMC7002574.
20. Jiao, W, Atwal, G, Polak, P, Karlic, R, Cuppen, E, PCAWG Tumor Subtypes and Clinical Translation Working Group et al.. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun. 2020;11 (1):728. doi: 10.1038/s41467-019-13825-8. PubMed PMID:32024849 PubMed Central PMC7002586.
21. Paczkowska, M, Barenboim, J, Sintupisut, N, Fox, NS, Zhu, H, Abd-Rabbo, D et al.. Integrative pathway enrichment analysis of multivariate omics data. Nat Commun. 2020;11 (1):735. doi: 10.1038/s41467-019-13983-9. PubMed PMID:32024846 PubMed Central PMC7002665.
22. Cmero, M, Yuan, K, Ong, CS, Schröder, J, PCAWG Evolution and Heterogeneity Working Group, Corcoran, NM et al.. Inferring structural variant cancer cell fraction. Nat Commun. 2020;11 (1):730. doi: 10.1038/s41467-020-14351-8. PubMed PMID:32024845 PubMed Central PMC7002525.
23. Rubanova, Y, Shi, R, Harrigan, CF, Li, R, Wintersinger, J, Sahin, N et al.. Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nat Commun. 2020;11 (1):731. doi: 10.1038/s41467-020-14352-7. PubMed PMID:32024834 PubMed Central PMC7002414.
24. Zhang, Y, Chen, F, Fonseca, NA, He, Y, Fujita, M, Nakagawa, H et al.. High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. Nat Commun. 2020;11 (1):736. doi: 10.1038/s41467-019-13885-w. PubMed PMID:32024823 PubMed Central PMC7002524.
25. Bhandari, V, Li, CH, Bristow, RG, Boutros, PC, PCAWG Consortium. Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun. 2020;11 (1):737. doi: 10.1038/s41467-019-14052-x. PubMed PMID:32024819 PubMed Central PMC7002770.
26. Shuai, S, PCAWG Drivers and Functional Interpretation Working Group, Gallinger, S, Stein, LD, PCAWG Consortium. Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nat Commun. 2020;11 (1):734. doi: 10.1038/s41467-019-13929-1. PubMed PMID:32024818 PubMed Central PMC7002750.
27. Sieverling, L, Hong, C, Koser, SD, Ginsbach, P, Kleinheinz, K, Hutter, B et al.. Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun. 2020;11 (1):733. doi: 10.1038/s41467-019-13824-9. PubMed PMID:32024817 PubMed Central PMC7002710.

Search PubMed

1. Kallio, HML, Hieta, R, Latonen, L, Brofeldt, A, Annala, M, Kivinummi, K et al.. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. Br J Cancer. 2018;119 (3):347-356. doi: 10.1038/s41416-018-0172-0. PubMed PMID:29988112 PubMed Central PMC6070921.
2. Sainio, M, Visakorpi, T, Tolonen, T, Ilvesaro, J, Bova, GS. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer. Pathol Res Pract. 2018;214 (6):848-856. doi: 10.1016/j.prp.2018.04.015. PubMed PMID:29728311 .
3. Wedge, DC, Gundem, G, Mitchell, T, Woodcock, DJ, Martincorena, I, Ghori, M et al.. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet. 2018;50 (5):682-692. doi: 10.1038/s41588-018-0086-z. PubMed PMID:29662167 PubMed Central PMC6372064.
4. Högnäs, G, Kivinummi, K, Kallio, HML, Hieta, R, Ruusuvuori, P, Koskenalho, A et al.. Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues. Am J Surg Pathol. 2018;42 (1):103-115. doi: 10.1097/PAS.0000000000000961. PubMed PMID:28984675 .

Search PubMed

Jorma Isola – Cancer biology

2021-2024

1. Daveson, AJM, Stubbs, R, Polasek, TM, Isola, J, Anderson, R, Tye-Din, JA et al.. Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Gastroenterol Hepatol. 2024; :. doi: 10.1016/S2468-1253(24)00248-6. PubMed PMID:39521016 .
2. Dotsenko, V, Tewes, B, Hils, M, Pasternack, R, Isola, J, Taavela, J et al.. Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease. Nat Immunol. 2024;25 (7):1218-1230. doi: 10.1038/s41590-024-01867-0. PubMed PMID:38914866 PubMed Central PMC11224021.

Search PubMed

1. Isola, J, Mäki, M, Hils, M, Pasternack, R, Viiri, K, Dotsenko, V et al.. The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment. Int J Mol Sci. 2023;24 (13):. doi: 10.3390/ijms241310815. PubMed PMID:37445994 PubMed Central PMC10341493.
2. Tye-Din, JA, Daveson, AJM, Goel, G, Goldstein, KE, Hand, HL, Neff, KM et al.. Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study. Lancet Gastroenterol Hepatol. 2023;8 (5):446-457. doi: 10.1016/S2468-1253(22)00428-9. PubMed PMID:36898393 .

Search PubMed

1. Murray, JA, Syage, JA, Wu, TT, Dickason, MA, Ramos, AG, Van Dyke, C et al.. Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge. Gastroenterology. 2022;163 (6):1510-1521.e6. doi: 10.1053/j.gastro.2022.07.071. PubMed PMID:35931103 PubMed Central PMC9707643.
2. Närvä, E, Taskinen, ME, Lilla, S, Isomursu, A, Pietilä, M, Weltner, J et al.. MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1/OCT4 levels. iScience. 2022;25 (6):104459. doi: 10.1016/j.isci.2022.104459. PubMed PMID:35677646 PubMed Central PMC9167974.
3. Puttonen, M, Isola, J, Ylinen, O, Böhling, T, Koljonen, V, Sihto, H et al.. UV-induced local immunosuppression in the tumour microenvironment of eccrine porocarcinoma and poroma. Sci Rep. 2022;12 (1):5529. doi: 10.1038/s41598-022-09490-5. PubMed PMID:35365704 PubMed Central PMC8976087.
4. Bychkov, D, Joensuu, H, Nordling, S, Tiulpin, A, Kücükel, H, Lundin, M et al.. Outcome and Biomarker Supervised Deep Learning for Survival Prediction in Two Multicenter Breast Cancer Series. J Pathol Inform. 2022;13 :9. doi: 10.4103/jpi.jpi_29_21. PubMed PMID:35136676 PubMed Central PMC8794033.
5. Andriulli, A, Bevilacqua, A, Palmieri, O, Latiano, A, Fontana, R, Gioffreda, D et al.. Healthy and pro-inflammatory gut ecology plays a crucial role in the digestion and tolerance of a novel Gluten Friendly™ bread in celiac subjects: a randomized, double blind, placebo control study. Food Funct. 2022;13 (3):1299-1315. doi: 10.1039/d1fo00490e. PubMed PMID:35029612 .

Search PubMed

1. Taavela, J, Viiri, K, Välimäki, A, Sarin, J, Salonoja, K, Mäki, M et al.. Apolipoprotein A4 Defines the Villus-Crypt Border in Duodenal Specimens for Celiac Disease Morphometry. Front Immunol. 2021;12 :713854. doi: 10.3389/fimmu.2021.713854. PubMed PMID:34394117 PubMed Central PMC8358775.
2. Schuppan, D, Mäki, M, Lundin, KEA, Isola, J, Friesing-Sosnik, T, Taavela, J et al.. A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease. N Engl J Med. 2021;385 (1):35-45. doi: 10.1056/NEJMoa2032441. PubMed PMID:34192430 .
3. Repo, M, Hannula, M, Taavela, J, Hyttinen, J, Isola, J, Hiltunen, P et al.. Iron Transporter Protein Expressions in Children with Celiac Disease. Nutrients. 2021;13 (3):. doi: 10.3390/nu13030776. PubMed PMID:33673530 PubMed Central PMC7997288.
4. Bychkov, D, Linder, N, Tiulpin, A, Kücükel, H, Lundin, M, Nordling, S et al.. Deep learning identifies morphological features in breast cancer predictive of cancer ERBB2 status and trastuzumab treatment efficacy. Sci Rep. 2021;11 (1):4037. doi: 10.1038/s41598-021-83102-6. PubMed PMID:33597560 PubMed Central PMC7890057.
5. Alanko, J, Tanner, M, Vanninen, R, Auvinen, A, Isola, J. Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis. Breast Cancer Res Treat. 2021;187 (1):267-274. doi: 10.1007/s10549-020-06060-z. PubMed PMID:33420595 PubMed Central PMC8062374.
6. Popp, A, Taavela, J, Graziano, P, Parente, P, Covelli, C, Lamacchia, C et al.. Correction to: A New Intraepithelial γδ T-Lymphocyte Marker for Celiac Disease Classification in Formalin-Fixed Paraffin-Embedded (FFPE) Duodenal Biopsies. Dig Dis Sci. 2021;66 (12):4572. doi: 10.1007/s10620-020-06731-3. PubMed PMID:33236317 PubMed Central PMC8589807.
7. Popp, A, Taavela, J, Graziano, P, Parente, P, Covelli, C, Lamacchia, C et al.. A New Intraepithelial γδ T-Lymphocyte Marker for Celiac Disease Classification in Formalin-Fixed Paraffin-Embedded (FFPE) Duodenal Biopsies. Dig Dis Sci. 2021;66 (10):3352-3358. doi: 10.1007/s10620-020-06680-x. PubMed PMID:33140183 PubMed Central PMC8449760.
8. Dotsenko, V, Oittinen, M, Taavela, J, Popp, A, Peräaho, M, Staff, S et al.. Genome-Wide Transcriptomic Analysis of Intestinal Mucosa in Celiac Disease Patients on a Gluten-Free Diet and Postgluten Challenge. Cell Mol Gastroenterol Hepatol. 2021;11 (1):13-32. doi: 10.1016/j.jcmgh.2020.07.010. PubMed PMID:32745639 PubMed Central PMC7593586.

Search PubMed

Pirkko Kellokumpu-Lehtinen – Radiotherapy and Oncology

2018-2024

1. Joensuu, H, Fraser, J, Wildiers, H, Huovinen, R, Auvinen, P, Utriainen, M et al.. Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial. JAMA Netw Open. 2024;7 (8):e2429772. doi: 10.1001/jamanetworkopen.2024.29772. PubMed PMID:39186271 .
2. Blomqvist, C, Vehmanen, L, Kellokumpu-Lehtinen, PL, Huovinen, R, Ruohola, J, Penttinen, H et al.. Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study. Breast Cancer Res Treat. 2024;206 (1):57-65. doi: 10.1007/s10549-024-07252-7. PubMed PMID:38561578 PubMed Central PMC11182844.
3. Mäenpää, N, Tiainen, L, Hämäläinen, M, Luukkaala, T, Tanner, M, Lahdenperä, O et al.. Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer. BMC Cancer. 2024;24 (1):331. doi: 10.1186/s12885-024-12070-7. PubMed PMID:38468231 PubMed Central PMC10929217.
4. Tolaney, SM, Guarneri, V, Seo, JH, Cruz, J, Abreu, MH, Takahashi, M et al.. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer. Eur J Cancer. 2024;199 :113555. doi: 10.1016/j.ejca.2024.113555. PubMed PMID:38244363 .
5. Reinikainen, P, Lehtinen, I, Luukkaala, T, Kellokumpu-Lehtinen, PL. Safer and More Convenient Modern Curative Radiotherapy for Patients With Early Prostate Cancer. Anticancer Res. 2024;44 (1):139-150. doi: 10.21873/anticanres.16796. PubMed PMID:38159980 .

Search PubMed

1. Lehtonen, M, Kellokumpu-Lehtinen, PL. The past and present of prostate cancer and its treatment and diagnostics: A historical review. SAGE Open Med. 2023;11 :20503121231216837. doi: 10.1177/20503121231216837. PubMed PMID:38050625 PubMed Central PMC10693792.
2. Haapasalmi, S, Lehto, JT, Metsänoja, R, Kellokumpu-Lehtinen, PI, Piili, RP. End-of-life Decision-making Differs Between a Cancer and a Dementia Patient: Influences of the Physician’s Background Factors. Anticancer Res. 2023;43 (8):3631-3638. doi: 10.21873/anticanres.16543. PubMed PMID:37500170 .
3. Moisander, M, Skyttä, T, Kivistö, S, Huhtala, H, Nikus, K, Virtanen, V et al.. Radiotherapy-induced diffuse myocardial fibrosis in early-stage breast cancer patients – multimodality imaging study with six-year follow-up. Radiat Oncol. 2023;18 (1):124. doi: 10.1186/s13014-023-02319-z. PubMed PMID:37496091 PubMed Central PMC10373367.
4. Lehtomäki, K, Heervä, E, Kellokumpu-Lehtinen, PL, Mustonen, H, Salminen, T, Joensuu, H et al.. Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer. Int J Mol Sci. 2023;24 (7):. doi: 10.3390/ijms24076753. PubMed PMID:37047727 PubMed Central PMC10094778.
5. Gillessen, S, Bossi, A, Davis, ID, de Bono, J, Fizazi, K, James, ND et al.. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023;185 :178-215. doi: 10.1016/j.ejca.2023.02.018. PubMed PMID:37003085 .
6. Metsälä, O, Wahlström, G, Taimen, P, Kellokumpu-Lehtinen, PL, Schleutker, J. Transcripts of the Prostate Cancer-Associated Gene Are Retained in the Nuclei of Prostatic Epithelial Cells. Int J Mol Sci. 2023;24 (2):. doi: 10.3390/ijms24021052. PubMed PMID:36674564 PubMed Central PMC9865797.
7. Gillessen, S, Bossi, A, Davis, ID, de Bono, J, Fizazi, K, James, ND et al.. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023;83 (3):267-293. doi: 10.1016/j.eururo.2022.11.002. PubMed PMID:36494221 PubMed Central PMC7614721.
8. Reinikainen, P, Lehtonen, M, Lehtinen, I, Luukkaala, T, Sintonen, H, Kellokumpu-Lehtinen, PL et al.. Health-related Quality of Life of Patients Treated With Different Fractionation Schedules for Early Prostate Cancer Compared to the Age-standardized General Male Population. Clin Genitourin Cancer. 2023;21 (1):146-154. doi: 10.1016/j.clgc.2022.07.013. PubMed PMID:36038484 .

Search PubMed

1. Gillessen, S, Bossi, A, Davis, ID, de Bono, J, Fizazi, K, James, ND et al.. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023;83 (3):267-293. doi: 10.1016/j.eururo.2022.11.002. PubMed PMID:36494221 PubMed Central PMC7614721.
2. Reinikainen, P, Lehtonen, M, Lehtinen, I, Luukkaala, T, Sintonen, H, Kellokumpu-Lehtinen, PL et al.. Health-related Quality of Life of Patients Treated With Different Fractionation Schedules for Early Prostate Cancer Compared to the Age-standardized General Male Population. Clin Genitourin Cancer. 2023;21 (1):146-154. doi: 10.1016/j.clgc.2022.07.013. PubMed PMID:36038484 .
3. Kokkonen, K, Kellokumpu-Lehtinen, PL, Kankaanpää, M, Nikander, R, Penttinen, HM, Utriainen, M et al.. Factors predicting long-term physical activity of breast cancer survivors. 5-year-follow-up of the BREX exercise intervention study. Acta Oncol. 2022;61 (10):1200-1208. doi: 10.1080/0284186X.2022.2103388. PubMed PMID:35881067 .
4. Lehtonen, M, Sormunen, J, Luukkaala, T, Marttila, T, McDermott, R, Joensuu, T et al.. 2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial. Acta Oncol. 2022;61 (8):963-971. doi: 10.1080/0284186X.2022.2098680. PubMed PMID:35847998 .
5. Tuohinen, SS, Aula, H, Skyttä, T, Huhtala, H, Keski-Pukkila, K, Nikus, K et al.. A Higher Mean Heart Radiation Dose Induces Higher Frequency of Multiple Cardiac Changes. Anticancer Res. 2022;42 (5):2519-2529. doi: 10.21873/anticanres.15730. PubMed PMID:35489742 .
6. Tuohinen, SS, Skytta, T, Huhtala, H, Virtanen, V, Kellokumpu-Lehtinen, PL, Raatikainen, P et al.. Dynamic Integrated Backscatter Detects Radiotherapy-induced Cardiac Changes Better than Strain Analysis – A Prospective Three-year Study. Anticancer Res. 2022;42 (5):2507-2517. doi: 10.21873/anticanres.15729. PubMed PMID:35489739 .
7. Reinikainen, P, Kapanen, M, Luukkaala, T, Kellokumpu-Lehtinen, PL. Acute Side-effects of Different Radiotherapy Treatment Schedules in Early Prostate Cancer. Anticancer Res. 2022;42 (5):2553-2565. doi: 10.21873/anticanres.15733. PubMed PMID:35489724 .
8. Lehtomäki, K, Stedt, HP, Osterlund, E, Muhonen, T, Soveri, LM, Halonen, P et al.. Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study. Cancers (Basel). 2022;14 (7):. doi: 10.3390/cancers14071713. PubMed PMID:35406485 PubMed Central PMC8996978.
9. Bychkov, D, Joensuu, H, Nordling, S, Tiulpin, A, Kücükel, H, Lundin, M et al.. Outcome and Biomarker Supervised Deep Learning for Survival Prediction in Two Multicenter Breast Cancer Series. J Pathol Inform. 2022;13 :9. doi: 10.4103/jpi.jpi_29_21. PubMed PMID:35136676 PubMed Central PMC8794033.
10. Poikonen-Saksela, P, Kolokotroni, E, Vehmanen, L, Mattson, J, Stamatakos, G, Huovinen, R et al.. A graphical LASSO analysis of global quality of life, sub scales of the EORTC QLQ-C30 instrument and depression in early breast cancer. Sci Rep. 2022;12 (1):2112. doi: 10.1038/s41598-022-06138-2. PubMed PMID:35136160 PubMed Central PMC8826362.
11. Joensuu, H, Kellokumpu-Lehtinen, PL, Huovinen, R, Jukkola, A, Tanner, M, Ahlgren, J et al.. Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. J Clin Oncol. 2022;40 (10):1051-1058. doi: 10.1200/JCO.21.02054. PubMed PMID:35020465 PubMed Central PMC8966968.
12. Loi, S, Salgado, R, Adams, S, Pruneri, G, Francis, PA, Lacroix-Triki, M et al.. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. NPJ Breast Cancer. 2022;8 (1):3. doi: 10.1038/s41523-021-00362-1. PubMed PMID:35017545 PubMed Central PMC8752727.
13. Lehtonen, M, Sormunen, J, Hjälm-Eriksson, M, Thellenberg-Karlsson, C, Huttunen, T, Ginman, C et al.. Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study. Anticancer Res. 2022;42 (1):87-92. doi: 10.21873/anticanres.15460. PubMed PMID:34969712 .
14. Bärlund, M, Takala, L, Tianen, L, Kellokumpu-Lehtinen, PL. Real-world Evidence of Implementing eHealth Enables Fluent Symptom-based Follow-up of a Growing Number of Patients with Breast Cancer with the Same Healthcare Resources. Clin Breast Cancer. 2022;22 (3):261-268. doi: 10.1016/j.clbc.2021.09.005. PubMed PMID:34657816 .

Search PubMed

1. Bärlund, M, Takala, L, Tianen, L, Kellokumpu-Lehtinen, PL. Real-world Evidence of Implementing eHealth Enables Fluent Symptom-based Follow-up of a Growing Number of Patients with Breast Cancer with the Same Healthcare Resources. Clin Breast Cancer. 2022;22 (3):261-268. doi: 10.1016/j.clbc.2021.09.005. PubMed PMID:34657816 .
2. Vähäaho, N, Hakamies-Blomqvist, L, Blomqvist, C, Kellokumpu-Lehtinen, PL, Huovinen, R, Saarto, T et al.. Sense of Coherence as Predictor of Quality of Life in Early Breast Cancer Patients. Anticancer Res. 2021;41 (10):5045-5052. doi: 10.21873/anticanres.15319. PubMed PMID:34593453 .
3. Choueiri, TK, Tomczak, P, Park, SH, Venugopal, B, Ferguson, T, Chang, YH et al.. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021;385 (8):683-694. doi: 10.1056/NEJMoa2106391. PubMed PMID:34407342 .
4. Tuohinen, SS, Skyttä, T, Huhtala, H, Poutanen, T, Virtanen, V, Kellokumpu-Lehtinen, PL et al.. 3-Year Follow-Up of Radiation-Associated Changes in Diastolic Function by Speckle Tracking Echocardiography. JACC CardioOncol. 2021;3 (2):277-289. doi: 10.1016/j.jaccao.2021.03.005. PubMed PMID:34396335 PubMed Central PMC8352342.
5. Lehtomäki, K, Mustonen, H, Kellokumpu-Lehtinen, PL, Joensuu, H, Hermunen, K, Soveri, LM et al.. Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer. Cancers (Basel). 2021;13 (15):. doi: 10.3390/cancers13153892. PubMed PMID:34359796 PubMed Central PMC8345682.
6. Jasu, J, Tolonen, T, Antonarakis, ES, Beltran, H, Halabi, S, Eisenberger, MA et al.. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. Eur Urol Open Sci. 2021;30 :47-62. doi: 10.1016/j.euros.2021.05.011. PubMed PMID:34337548 PubMed Central PMC8317817.
7. Haapasalmi, S, Piili, RP, Metsänoja, R, Kellokumpu-Lehtinen, PI, Lehto, JT. Physicians’ decreased tendency to choose palliative care for patients with advanced dementia between 1999 and 2015. BMC Palliat Care. 2021;20 (1):119. doi: 10.1186/s12904-021-00811-5. PubMed PMID:34311739 PubMed Central PMC8312352.
8. Schmidt, M, Edlund, K, Hengstler, JG, Heimes, AS, Almstedt, K, Lebrecht, A et al.. Prognostic Impact of Immunoglobulin Kappa C in Early Breast Cancer. Cancers (Basel). 2021;13 (14):. doi: 10.3390/cancers13143626. PubMed PMID:34298839 PubMed Central PMC8304855.
9. Roine, E, Sintonen, H, Kellokumpu-Lehtinen, PL, Penttinen, H, Utriainen, M, Vehmanen, L et al.. Long-term health-related quality of life of breast cancer survivors remains impaired compared to the age-matched general population especially in young women. Results from the prospective controlled BREX exercise study. Breast. 2021;59 :110-116. doi: 10.1016/j.breast.2021.06.012. PubMed PMID:34225091 PubMed Central PMC8264211.
10. Aho, S, Vuoristo, MS, Raitanen, J, Mansikkamäki, K, Alanko, J, Vähä-Ypyä, H et al.. Higher number of steps and breaks during sedentary behaviour are associated with better lipid profiles. BMC Public Health. 2021;21 (1):629. doi: 10.1186/s12889-021-10656-5. PubMed PMID:33789632 PubMed Central PMC8010961.
11. Bychkov, D, Linder, N, Tiulpin, A, Kücükel, H, Lundin, M, Nordling, S et al.. Deep learning identifies morphological features in breast cancer predictive of cancer ERBB2 status and trastuzumab treatment efficacy. Sci Rep. 2021;11 (1):4037. doi: 10.1038/s41598-021-83102-6. PubMed PMID:33597560 PubMed Central PMC7890057.
12. Takala, L, Kuusinen, TE, Skyttä, T, Kellokumpu-Lehtinen, PL, Bärlund, M. Electronic Patient-reported Outcomes During Breast Cancer Adjuvant Radiotherapy. Clin Breast Cancer. 2021;21 (3):e252-e270. doi: 10.1016/j.clbc.2020.10.004. PubMed PMID:33229222 .
13. Vehmanen, L, Sievänen, H, Kellokumpu-Lehtinen, P, Nikander, R, Huovinen, R, Ruohola, J et al.. Five-year follow-up results of aerobic and impact training on bone mineral density in early breast cancer patients. Osteoporos Int. 2021;32 (3):473-482. doi: 10.1007/s00198-020-05611-w. PubMed PMID:32886189 PubMed Central PMC7929955.

Search PubMed

1. Kellokumpu-Lehtinen, PL, Marttila, T, Jekunen, A, Hervonen, P, Klintrup, K, Kataja, V et al.. Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel – A Final Analysis of the Prosty II Trial. Anticancer Res. 2020;40 (12):6915-6921. doi: 10.21873/anticanres.14715. PubMed PMID:33288585 .
2. Takala, L, Kuusinen, TE, Skyttä, T, Kellokumpu-Lehtinen, PL, Bärlund, M. Electronic Patient-reported Outcomes During Breast Cancer Adjuvant Radiotherapy. Clin Breast Cancer. 2021;21 (3):e252-e270. doi: 10.1016/j.clbc.2020.10.004. PubMed PMID:33229222 .
3. Kellokumpu-Lehtinen, PL, Hjälm-Eriksson, M, Thellenberg-Karlsson, C, Åström, L, Franzen, L, Fransson, AF et al.. Corrigendum re “Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial” [Eur Urol 2019;76:823-30]. Eur Urol. 2020;78 (6):e241-e242. doi: 10.1016/j.eururo.2020.08.035. PubMed PMID:32893063 .
4. Vehmanen, L, Sievänen, H, Kellokumpu-Lehtinen, P, Nikander, R, Huovinen, R, Ruohola, J et al.. Five-year follow-up results of aerobic and impact training on bone mineral density in early breast cancer patients. Osteoporos Int. 2021;32 (3):473-482. doi: 10.1007/s00198-020-05611-w. PubMed PMID:32886189 PubMed Central PMC7929955.
5. Pollari, M, Pellinen, T, Karjalainen-Lindsberg, ML, Kellokumpu-Lehtinen, PL, Leivonen, SK, Leppä, S et al.. Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma. Eur J Haematol. 2020;105 (6):712-721. doi: 10.1111/ejh.13484. PubMed PMID:32632935 .
6. Lehtonen, M, Heiskanen, L, Reinikainen, P, Kellokumpu-Lehtinen, PL. Both comorbidity and worse performance status are associated with poorer overall survival after external beam radiotherapy for prostate cancer. BMC Cancer. 2020;20 (1):324. doi: 10.1186/s12885-020-06812-6. PubMed PMID:32295542 PubMed Central PMC7160996.
7. Swain, SM, Miles, D, Kim, SB, Im, YH, Im, SA, Semiglazov, V et al.. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21 (4):519-530. doi: 10.1016/S1470-2045(19)30863-0. PubMed PMID:32171426 .
8. Roine, E, Sintonen, H, Kellokumpu-Lehtinen, PL, Penttinen, H, Utriainen, M, Vehmanen, L et al.. Health-related Quality of Life of Breast Cancer Survivors Attending an Exercise Intervention Study: A Five-year Follow-up. In Vivo. 2020;34 (2):667-674. doi: 10.21873/invivo.11821. PubMed PMID:32111767 PubMed Central PMC7157873.
9. Sonnenblick, A, Salmon-Divon, M, Salgado, R, Dvash, E, Pondé, N, Zahavi, T et al.. Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. Int J Cancer. 2020;147 (1):266-276. doi: 10.1002/ijc.32859. PubMed PMID:31904863 .
10. Aula, H, Skyttä, T, Tuohinen, S, Luukkaala, T, Hämäläinen, M, Virtanen, V et al.. ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer. Breast. 2020;49 :183-186. doi: 10.1016/j.breast.2019.12.001. PubMed PMID:31862685 PubMed Central PMC7375584.

Search PubMed

1. Aula, H, Skyttä, T, Tuohinen, S, Luukkaala, T, Hämäläinen, M, Virtanen, V et al.. ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer. Breast. 2020;49 :183-186. doi: 10.1016/j.breast.2019.12.001. PubMed PMID:31862685 PubMed Central PMC7375584.
2. Lehtomaki, KI, Lahtinen, LI, Rintanen, N, Kuopio, T, Kholova, I, Makela, R et al.. Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case. Anticancer Res. 2019;39 (11):5867-5877. doi: 10.21873/anticanres.13791. PubMed PMID:31704811 .
3. Vuorinen, RL, Paunu, N, Turpeenniemi-Hujanen, T, Reunamo, T, Jekunen, A, Kataja, V et al.. Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects. Anticancer Res. 2019;39 (10):5559-5564. doi: 10.21873/anticanres.13749. PubMed PMID:31570450 .
4. Kaikkonen, E, Ettala, O, Nikulainen, I, Taimen, P, Lehtinen, I, Boström, PJ et al.. rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer. Anticancer Res. 2019;39 (10):5353-5359. doi: 10.21873/anticanres.13728. PubMed PMID:31570429 .
5. Aula, H, Skyttä, T, Tuohinen, S, Luukkaala, T, Hämäläinen, M, Virtanen, V et al.. Transforming growth factor beta 1 levels predict echocardiographic changes at three years after adjuvant radiotherapy for breast cancer. Radiat Oncol. 2019;14 (1):155. doi: 10.1186/s13014-019-1366-1. PubMed PMID:31470867 PubMed Central PMC6717329.
6. Kellokumpu-Lehtinen, PL, Hjälm-Eriksson, M, Thellenberg-Karlsson, C, Åström, L, Franzen, L, Fransson, AS et al.. Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial. Eur Urol. 2019;76 (6):823-830. doi: 10.1016/j.eururo.2019.08.010. PubMed PMID:31443961 .
7. Piili, RP, Lehto, JT, Metsänoja, R, Hinkka, H, Kellokumpu-Lehtinen, PI. Has there been a change in the end-of-life decision-making over the past 16 years?. BMJ Support Palliat Care. 2019; :. doi: 10.1136/bmjspcare-2019-001802. PubMed PMID:31395612 .
8. Hackman, G, Taari, K, Tammela, TL, Matikainen, M, Kouri, M, Joensuu, T et al.. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. Eur Urol. 2019;76 (5):586-595. doi: 10.1016/j.eururo.2019.07.001. PubMed PMID:31375279 .
9. Tuohinen, SS, Skytta, T, Huhtala, H, Virtanen, V, Kellokumpu-Lehtinen, PL, Raatikainen, P et al.. Left Ventricular Speckle Tracking Echocardiography Changes Among Early-stage Breast Cancer Patients Three Years After Radiotherapy. Anticancer Res. 2019;39 (8):4227-4236. doi: 10.21873/anticanres.13584. PubMed PMID:31366510 .
10. Terävä, J, Tiainen, L, Lamminmäki, U, Kellokumpu-Lehtinen, PL, Pettersson, K, Gidwani, K et al.. Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma. PLoS One. 2019;14 (7):e0219480. doi: 10.1371/journal.pone.0219480. PubMed PMID:31344060 PubMed Central PMC6658058.
11. Tiainen, L, Korhonen, EA, Leppänen, VM, Luukkaala, T, Hämäläinen, M, Tanner, M et al.. High baseline Tie1 level predicts poor survival in metastatic breast cancer. BMC Cancer. 2019;19 (1):732. doi: 10.1186/s12885-019-5959-8. PubMed PMID:31340773 PubMed Central PMC6657075.
12. Auvray, M, Auclin, E, Barthelemy, P, Bono, P, Kellokumpu-Lehtinen, P, Gross-Goupil, M et al.. Erratum to ‘Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma’ [Eur J Cancer 108 (February 2019) 33-40]. Eur J Cancer. 2019;119 :200-201. doi: 10.1016/j.ejca.2019.04.012. PubMed PMID:31301937 .
13. Wu, X, Reinikainen, P, Kapanen, M, Vierikko, T, Ryymin, P, Kellokumpu-Lehtinen, PL et al.. Monitoring radiotherapy induced tissue changes in localized prostate cancer by multi-parametric magnetic resonance imaging (MP-MRI). Diagn Interv Imaging. 2019;100 (11):699-708. doi: 10.1016/j.diii.2019.06.003. PubMed PMID:31257114 .
14. Skyttä, T, Tuohinen, S, Luukkaala, T, Virtanen, V, Raatikainen, P, Kellokumpu-Lehtinen, PL et al.. Adjuvant radiotherapy-induced cardiac changes among patients with early breast cancer: a three-year follow-up study. Acta Oncol. 2019;58 (9):1250-1258. doi: 10.1080/0284186X.2019.1630751. PubMed PMID:31219359 .
15. Mannisto, S, Vähämurto, P, Pollari, M, Clausen, MR, Jyrkkiö, S, Kellokumpu-Lehtinen, PL et al.. Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma. Eur J Cancer. 2019;115 :27-36. doi: 10.1016/j.ejca.2019.04.004. PubMed PMID:31082690 .
16. Tiainen, L, Hämäläinen, M, Luukkaala, T, Tanner, M, Lahdenperä, O, Vihinen, P et al.. Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer. Clin Breast Cancer. 2019;19 (4):e522-e533. doi: 10.1016/j.clbc.2019.03.006. PubMed PMID:31029558 .
17. Alminoja, A, Piili, RP, Hinkka, H, Metsänoja, R, Hirvonen, O, Tyynelä-Korhonen, K et al.. Does Decision-making in End-of-life Care Differ Between Graduating Medical Students and Experienced Physicians?. In Vivo. 2019;33 (3):903-909. doi: 10.21873/invivo.11557. PubMed PMID:31028215 PubMed Central PMC6559926.
18. Penttinen, H, Utriainen, M, Kellokumpu-Lehtinen, PL, Raitanen, J, Sievänen, H, Nikander, R et al.. Effectiveness of a 12-month Exercise Intervention on Physical Activity and Quality of Life of Breast Cancer Survivors; Five-year Results of the BREX-study. In Vivo. 2019;33 (3):881-888. doi: 10.21873/invivo.11554. PubMed PMID:31028212 PubMed Central PMC6559915.
19. Loi, S, Drubay, D, Adams, S, Pruneri, G, Francis, PA, Lacroix-Triki, M et al.. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019;37 (7):559-569. doi: 10.1200/JCO.18.01010. PubMed PMID:30650045 PubMed Central PMC7010425.
20. Auvray, M, Auclin, E, Barthelemy, P, Bono, P, Kellokumpu-Lehtinen, P, Gross-Goupil, M et al.. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer. 2019;108 :33-40. doi: 10.1016/j.ejca.2018.11.031. PubMed PMID:30616146 .
21. Takala, L, Bärlund, M, Kellokumpu-Lehtinen, PL. Effective Antiemetic Therapy Is Important With Adjuvant Anthracycline-based Chemotherapy in Breast Cancer. Anticancer Res. 2019;39 (1):279-283. doi: 10.21873/anticanres.13108. PubMed PMID:30591469 .
22. Lehto, US, Ojanen, M, Väkevä, A, Dyba, T, Aromaa, A, Kellokumpu-Lehtinen, P et al.. Early quality-of-life and psychological predictors of disease-free time and survival in localized prostate cancer. Qual Life Res. 2019;28 (3):677-686. doi: 10.1007/s11136-018-2069-z. PubMed PMID:30511254 PubMed Central PMC6394517.
23. Leivonen, SK, Pollari, M, Brück, O, Pellinen, T, Autio, M, Karjalainen-Lindsberg, ML et al.. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica. 2019;104 (2):338-346. doi: 10.3324/haematol.2018.200105. PubMed PMID:30237271 PubMed Central PMC6355505.

Search PubMed

1. Lehto, US, Ojanen, M, Väkevä, A, Dyba, T, Aromaa, A, Kellokumpu-Lehtinen, P et al.. Early quality-of-life and psychological predictors of disease-free time and survival in localized prostate cancer. Qual Life Res. 2019;28 (3):677-686. doi: 10.1007/s11136-018-2069-z. PubMed PMID:30511254 PubMed Central PMC6394517.
2. Aula, H, Skyttä, T, Tuohinen, S, Luukkaala, T, Hämäläinen, M, Virtanen, V et al.. Decreases in TGF-β1 and PDGF levels are associated with echocardiographic changes during adjuvant radiotherapy for breast cancer. Radiat Oncol. 2018;13 (1):201. doi: 10.1186/s13014-018-1150-7. PubMed PMID:30340644 PubMed Central PMC6194684.
3. Wu, X, Reinikainen, P, Kapanen, M, Vierikko, T, Ryymin, P, Kellokumpu-Lehtinen, PL et al.. Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage. Contrast Media Mol Imaging. 2018;2018 :3181258. doi: 10.1155/2018/3181258. PubMed PMID:30327584 PubMed Central PMC6169212.
4. Leivonen, SK, Pollari, M, Brück, O, Pellinen, T, Autio, M, Karjalainen-Lindsberg, ML et al.. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica. 2019;104 (2):338-346. doi: 10.3324/haematol.2018.200105. PubMed PMID:30237271 PubMed Central PMC6355505.
5. Kaikkonen, E, Rantapero, T, Zhang, Q, Taimen, P, Laitinen, V, Kallajoki, M et al.. ANO7 is associated with aggressive prostate cancer. Int J Cancer. 2018;143 (10):2479-2487. doi: 10.1002/ijc.31746. PubMed PMID:30157291 PubMed Central PMC6589920.
6. Pollari, M, Brück, O, Pellinen, T, Vähämurto, P, Karjalainen-Lindsberg, ML, Mannisto, S et al.. PD-L1 tumor-associated macrophages and PD-1 tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. Haematologica. 2018;103 (11):1908-1914. doi: 10.3324/haematol.2018.197194. PubMed PMID:30026337 PubMed Central PMC6278972.
7. Piili, RP, Lehto, JT, Luukkaala, T, Hinkka, H, Kellokumpu-Lehtinen, PI. Does special education in palliative medicine make a difference in end-of-life decision-making?. BMC Palliat Care. 2018;17 (1):94. doi: 10.1186/s12904-018-0349-6. PubMed PMID:30021586 PubMed Central PMC6052558.
8. Joensuu, H, Fraser, J, Wildiers, H, Huovinen, R, Auvinen, P, Utriainen, M et al.. Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial. JAMA Oncol. 2018;4 (9):1199-1206. doi: 10.1001/jamaoncol.2018.1380. PubMed PMID:29852043 PubMed Central PMC6143012.
9. Piili, RP, Metsänoja, R, Hinkka, H, Kellokumpu-Lehtinen, PI, Lehto, JT. Changes in attitudes towards hastened death among Finnish physicians over the past sixteen years. BMC Med Ethics. 2018;19 (1):40. doi: 10.1186/s12910-018-0290-5. PubMed PMID:29843682 PubMed Central PMC5975714.
10. Tuohinen, SS, Keski-Pukkila, K, Skyttä, T, Huhtala, H, Virtanen, V, Kellokumpu-Lehtinen, PL et al.. Radiotherapy-induced Early ECG Changes and Their Comparison with Echocardiography in Patients with Early-stage Breast Cancer. Anticancer Res. 2018;38 (4):2207-2215. doi: 10.21873/anticanres.12463. PubMed PMID:29599341 .
11. Motzer, RJ, Tannir, NM, McDermott, DF, Arén Frontera, O, Melichar, B, Choueiri, TK et al.. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378 (14):1277-1290. doi: 10.1056/NEJMoa1712126. PubMed PMID:29562145 PubMed Central PMC5972549.
12. Sperinde, J, Huang, W, Vehtari, A, Chenna, A, Kellokumpu-Lehtinen, PL, Winslow, J et al.. p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial. Clin Cancer Res. 2018;24 (13):3046-3052. doi: 10.1158/1078-0432.CCR-17-3250. PubMed PMID:29535130 .
13. Schmidt, M, Weyer-Elberich, V, Hengstler, JG, Heimes, AS, Almstedt, K, Gerhold-Ay, A et al.. Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. Breast Cancer Res. 2018;20 (1):15. doi: 10.1186/s13058-018-0942-x. PubMed PMID:29482642 PubMed Central PMC5827982.
14. Ahlgren, GM, Flodgren, P, Tammela, TLJ, Kellokumpu-Lehtinen, P, Borre, M, Angelsen, A et al.. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. Eur Urol. 2018;73 (6):870-876. doi: 10.1016/j.eururo.2018.01.012. PubMed PMID:29395502 .
15. Hietanen, T, Kapanen, M, Kellokumpu-Lehtinen, PL. Natural Killer Cell Viability After Hyperthermia Alone or Combined with Radiotherapy with or without Cytokines. Anticancer Res. 2018;38 (2):655-663. doi: 10.21873/anticanres.12269. PubMed PMID:29374687 .
16. Tuohinen, SS, Rankinen, J, Skyttä, T, Huhtala, H, Virtanen, V, Kellokumpu-Lehtinen, PL et al.. Associations between ECG changes and echocardiographic findings in patients with acute non-ST elevation myocardial infarction. J Electrocardiol. 2018;51 (2):188-194. doi: 10.1016/j.jelectrocard.2017.11.007. PubMed PMID:29174705 .
17. Pajamäki, N, Metso, S, Hakala, T, Ebeling, T, Huhtala, H, Ryödi, E et al.. Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf). 2018;88 (2):303-310. doi: 10.1111/cen.13519. PubMed PMID:29154445 .
18. Gillessen, S, Attard, G, Beer, TM, Beltran, H, Bossi, A, Bristow, R et al.. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73 (2):178-211. doi: 10.1016/j.eururo.2017.06.002. PubMed PMID:28655541 .

Search PubMed

Olli Lohi – Hematology and oncology

2020-2024

1. Malyukova, A, Lahnalampi, M, Falqués-Costa, T, Pölönen, P, Sipola, M, Mehtonen, J et al.. Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia. Genome Biol. 2024;25 (1):143. doi: 10.1186/s13059-024-03260-4. PubMed PMID:38822412 PubMed Central PMC11143599.
2. Pekkarinen, M, Nordfors, K, Uusi-Mäkelä, J, Kytölä, V, Hartewig, A, Huhtala, L et al.. Aberrant DNA methylation distorts developmental trajectories in atypical teratoid/rhabdoid tumors. Life Sci Alliance. 2024;7 (6):. doi: 10.26508/lsa.202302088. PubMed PMID:38499326 PubMed Central PMC10948937.

Search PubMed

1. Zapilko, V, Moisio, S, Parikka, M, Heinäniemi, M, Lohi, O. Generation of a Zebrafish Knock-In Model Recapitulating Childhood ETV6::RUNX1-Positive B-Cell Precursor Acute Lymphoblastic Leukemia. Cancers (Basel). 2023;15 (24):. doi: 10.3390/cancers15245821. PubMed PMID:38136366 PubMed Central PMC10871125.
2. Krali, O, Marincevic-Zuniga, Y, Arvidsson, G, Enblad, AP, Lundmark, A, Sayyab, S et al.. Multimodal classification of molecular subtypes in pediatric acute lymphoblastic leukemia. NPJ Precis Oncol. 2023;7 (1):131. doi: 10.1038/s41698-023-00479-5. PubMed PMID:38066241 PubMed Central PMC10709574.
3. Ventelä, J, Alanko, A, Auvinen, A, Lohi, O, Nikkilä, A. Dual direction associations between common autoimmune diseases and leukemia among children and young adults: A systematic review. Cancer Epidemiol. 2023;86 :102411. doi: 10.1016/j.canep.2023.102411. PubMed PMID:37423102 .
4. Heipertz, AE, Pajtler, KW, Pfaff, E, Schramm, K, Blattner-Johnson, M, Milde, T et al.. Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. JCO Precis Oncol. 2023;7 :e2300015. doi: 10.1200/PO.23.00015. PubMed PMID:37364231 .
5. Kilpeläinen, L, Nikkilä, A, Lohi, O. Pre-harvest CD34 cell counts predicted peripheral blood stem cell collection yields. Acta Paediatr. 2023;112 (10):2189-2190. doi: 10.1111/apa.16879. PubMed PMID:37332113 .
6. Hakkarainen, M, Kaaja, I, Douglas, SPM, Vulliamy, T, Dokal, I, Soulier, J et al.. The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia. Blood. 2023;141 (23):2853-2866. doi: 10.1182/blood.2022019425. PubMed PMID:36952636 .
7. Fischer, A, Lersch, R, de Andrade Krätzig, N, Strong, A, Friedrich, MJ, Weber, J et al.. interrogation of regulatory genomes reveals extensive quasi-insufficiency in cancer evolution. Cell Genom. 2023;3 (3):100276. doi: 10.1016/j.xgen.2023.100276. PubMed PMID:36950387 PubMed Central PMC10025556.
8. Saralahti, AK, Harjula, SE, Rantapero, T, Uusi-Mäkelä, MIE, Kaasinen, M, Junno, M et al.. Characterization of the innate immune response to Streptococcus pneumoniae infection in zebrafish. PLoS Genet. 2023;19 (1):e1010586. doi: 10.1371/journal.pgen.1010586. PubMed PMID:36622851 PubMed Central PMC9858863.

Search PubMed

1. Peterziel, H, Jamaladdin, N, ElHarouni, D, Gerloff, XF, Herter, S, Fiesel, P et al.. Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM. NPJ Precis Oncol. 2022;6 (1):94. doi: 10.1038/s41698-022-00335-y. PubMed PMID:36575299 PubMed Central PMC9794727.
2. Pilheden, M, Ahlgren, L, Hyrenius-Wittsten, A, Gonzalez-Pena, V, Sturesson, H, Hansen Marquart, HV et al.. Duplex Sequencing Uncovers Recurrent Low-frequency Cancer-associated Mutations in Infant and Childhood -rearranged Acute Leukemia. Hemasphere. 2022;6 (10):e785. doi: 10.1097/HS9.0000000000000785. PubMed PMID:36204688 PubMed Central PMC9529062.
3. Andersson, NG, Rathe, M, Mølle, I, Jarvis, KB, Hoffmann, M, Huurre, A et al.. A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management. Br J Haematol. 2022;199 (1):117-121. doi: 10.1111/bjh.18397. PubMed PMID:35922061 PubMed Central PMC9804349.
4. Abuhamed, J, Nikkilä, A, Raitanen, J, Alimam, W, Lohi, O, Pitkäniemi, J et al.. Incidence trends of childhood central nervous system tumors in Finland 1990-2017. BMC Cancer. 2022;22 (1):784. doi: 10.1186/s12885-022-09862-0. PubMed PMID:35850678 PubMed Central PMC9290294.
5. Vuorenoja, S, Vettenranta, K, Lohi, O. Successful eradication of chronic myeloid leukemia in a child despite allogeneic graft rejection. Cancer Rep (Hoboken). 2022;5 (10):e1663. doi: 10.1002/cnr2.1663. PubMed PMID:35796282 PubMed Central PMC9575499.
6. Nikkilä, A, Lohi, O, Nieminen, N, Csonka, P. Trends in ferritin measurements in children and adolescents: A Finnish 9-year observational study. Acta Paediatr. 2022;111 (10):1933-1940. doi: 10.1111/apa.16454. PubMed PMID:35708115 PubMed Central PMC9541652.
7. Schober, SJ, Hallmen, E, Reßle, F, Gassmann, H, Prexler, C, Wawer, A et al.. No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy. Front Oncol. 2022;12 :878367. doi: 10.3389/fonc.2022.878367. PubMed PMID:35619911 PubMed Central PMC9127413.
8. Oksa, L, Mäkinen, A, Nikkilä, A, Hyvärinen, N, Laukkanen, S, Rokka, A et al.. Arginine Methyltransferase PRMT7 Deregulates Expression of RUNX1 Target Genes in T-Cell Acute Lymphoblastic Leukemia. Cancers (Basel). 2022;14 (9):. doi: 10.3390/cancers14092169. PubMed PMID:35565298 PubMed Central PMC9101393.
9. Laukkanen, S, Veloso, A, Yan, C, Oksa, L, Alpert, EJ, Do, D et al.. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia. Blood. 2022;140 (17):1891-1906. doi: 10.1182/blood.2021015106. PubMed PMID:35544598 PubMed Central PMC10082361.
10. Långström, S, Huurre, A, Kari, J, Lohi, O, Sievänen, H, Palmu, S et al.. Bioimpedance spinal needle provides high success and low complication rate in lumbar punctures of pediatric patients with acute lymphoblastic leukemia. Sci Rep. 2022;12 (1):6799. doi: 10.1038/s41598-022-10915-4. PubMed PMID:35474331 PubMed Central PMC9042945.
11. Ventelä, J, Nikkilä, A, Jukkola, A, Lohi, O. Incidence and outcomes of cancer in 16- to 17-year-old adolescents. Acta Paediatr. 2022;111 (2):442-444. doi: 10.1111/apa.16161. PubMed PMID:34689375 PubMed Central PMC9299452.

Search PubMed

1. Ventelä, J, Nikkilä, A, Jukkola, A, Lohi, O. Incidence and outcomes of cancer in 16- to 17-year-old adolescents. Acta Paediatr. 2022;111 (2):442-444. doi: 10.1111/apa.16161. PubMed PMID:34689375 PubMed Central PMC9299452.
2. van Tilburg, CM, Pfaff, E, Pajtler, KW, Langenberg, KPS, Fiesel, P, Jones, BC et al.. The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discov. 2021;11 (11):2764-2779. doi: 10.1158/2159-8290.CD-21-0094. PubMed PMID:34373263 PubMed Central PMC9414287.
3. Immonen, E, Nikkilä, A, Peltomäki, T, Aine, L, Lohi, O. Late adverse effects of childhood acute lymphoblastic leukemia treatment on developing dentition. Pediatr Blood Cancer. 2021;68 (9):e29200. doi: 10.1002/pbc.29200. PubMed PMID:34228397 .
4. Mäkinen, A, Nikkilä, A, Mehtonen, J, Teppo, S, Oksa, L, Nordlund, J et al.. Expression of BCL6 in paediatric B-cell acute lymphoblastic leukaemia and association with prognosis. Pathology. 2021;53 (7):875-882. doi: 10.1016/j.pathol.2021.02.013. PubMed PMID:34049715 .
5. Mäkinen, A, Nikkilä, A, Haapaniemi, T, Oksa, L, Mehtonen, J, Vänskä, M et al.. Associates with Proliferative Phenotype and Prognostic Features in B-Cell Acute Lymphoblastic Leukemia. Cancers (Basel). 2021;13 (7):. doi: 10.3390/cancers13071505. PubMed PMID:33805930 PubMed Central PMC8037952.
6. Winter, G, Kirschner-Schwabe, R, Groeneveld-Krentz, S, Escherich, G, Möricke, A, von Stackelberg, A et al.. Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome. Leukemia. 2021;35 (5):1475-1479. doi: 10.1038/s41375-021-01163-y. PubMed PMID:33580201 PubMed Central PMC8102191.

Search PubMed

1. Abuhamed, J, Nikkilä, A, Lohi, O, Auvinen, A. Trends of computed tomography use among children in Finland. Eur J Radiol Open. 2020;7 :100290. doi: 10.1016/j.ejro.2020.100290. PubMed PMID:33335951 PubMed Central PMC7733003.
2. Mehtonen, J, Teppo, S, Lahnalampi, M, Kokko, A, Kaukonen, R, Oksa, L et al.. Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1-positive pediatric leukemia identifies drug-targetable transcription factor activities. Genome Med. 2020;12 (1):99. doi: 10.1186/s13073-020-00799-2. PubMed PMID:33218352 PubMed Central PMC7679990.
3. Dufva, O, Pölönen, P, Brück, O, Keränen, MAI, Klievink, J, Mehtonen, J et al.. Immunogenomic Landscape of Hematological Malignancies. Cancer Cell. 2020;38 (3):424-428. doi: 10.1016/j.ccell.2020.08.019. PubMed PMID:32931743 .
4. Laukkanen, S, Oksa, L, Nikkilä, A, Lahnalampi, M, Parikka, M, Seki, M et al.. SIX6 is a TAL1-regulated transcription factor in T-ALL and associated with inferior outcome. Leuk Lymphoma. 2020;61 (13):3089-3100. doi: 10.1080/10428194.2020.1804560. PubMed PMID:32835548 .
5. Immonen, E, Aine, L, Nikkilä, A, Parikka, M, Grönroos, M, Vepsäläinen, K et al.. Randomized controlled and double-blinded study of Caphosol versus saline oral rinses in pediatric patients with cancer. Pediatr Blood Cancer. 2020;67 (10):e28520. doi: 10.1002/pbc.28520. PubMed PMID:32725875 .
6. Chan, LN, Murakami, MA, Robinson, ME, Caeser, R, Sadras, T, Lee, J et al.. Signalling input from divergent pathways subverts B cell transformation. Nature. 2020;583 (7818):845-851. doi: 10.1038/s41586-020-2513-4. PubMed PMID:32699415 PubMed Central PMC7394729.
7. Dufva, O, Pölönen, P, Brück, O, Keränen, MAI, Klievink, J, Mehtonen, J et al.. Immunogenomic Landscape of Hematological Malignancies. Cancer Cell. 2020;38 (3):380-399.e13. doi: 10.1016/j.ccell.2020.06.002. PubMed PMID:32649887 .
8. Karalexi, MA, Dessypris, N, Ma, X, Spector, LG, Marcotte, E, Clavel, J et al.. Age-, sex- and disease subtype-related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysis. Eur J Cancer. 2020;130 :1-11. doi: 10.1016/j.ejca.2020.01.018. PubMed PMID:32163883 .
9. Nikkilä, A, Raitanen, J, Lohi, O, Auvinen, A. Radiation exposure from computerized tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE). Haematologica. 2020;105 (3):849-850. doi: 10.3324/haematol.2019.245704. PubMed PMID:32115415 PubMed Central PMC7049358.
10. Grönroos, T, Mäkinen, A, Laukkanen, S, Mehtonen, J, Nikkilä, A, Oksa, L et al.. Clinicopathological features and prognostic value of SOX11 in childhood acute lymphoblastic leukemia. Sci Rep. 2020;10 (1):2043. doi: 10.1038/s41598-020-58970-z. PubMed PMID:32029838 PubMed Central PMC7005266.
11. Nikkilä, A, Arvela, H, Mehtonen, J, Raitanen, J, Heinäniemi, M, Lohi, O et al.. Predicting residential radon concentrations in Finland: Model development, validation, and application to childhood leukemia. Scand J Work Environ Health. 2020;46 (3):278-292. doi: 10.5271/sjweh.3867. PubMed PMID:31763683 .
12. Harjula, SE, Saralahti, AK, Ojanen, MJT, Rantapero, T, Uusi-Mäkelä, MIE, Nykter, M et al.. Characterization of immune response against Mycobacterium marinum infection in the main hematopoietic organ of adult zebrafish (Danio rerio). Dev Comp Immunol. 2020;103 :103523. doi: 10.1016/j.dci.2019.103523. PubMed PMID:31626817 .
13. Heikkilä, P, Kokko, P, Lohi, O, Korppi, M. Nursing intensity scores did not correlate well with reimbursement claims for infant bronchiolitis. Acta Paediatr. 2020;109 (1):140-146. doi: 10.1111/apa.14926. PubMed PMID:31269265 .

Search PubMed

1. Karppinen, S, Lohi, O, Vihola, M. Prediction of leukocyte counts during paediatric acute lymphoblastic leukaemia maintenance therapy. Sci Rep. 2019;9 (1):18076. doi: 10.1038/s41598-019-54492-5. PubMed PMID:31792398 PubMed Central PMC6889389.
2. Nikkilä, A, Arvela, H, Mehtonen, J, Raitanen, J, Heinäniemi, M, Lohi, O et al.. Predicting residential radon concentrations in Finland: Model development, validation, and application to childhood leukemia. Scand J Work Environ Health. 2020;46 (3):278-292. doi: 10.5271/sjweh.3867. PubMed PMID:31763683 .
3. Harjula, SE, Saralahti, AK, Ojanen, MJT, Rantapero, T, Uusi-Mäkelä, MIE, Nykter, M et al.. Characterization of immune response against Mycobacterium marinum infection in the main hematopoietic organ of adult zebrafish (Danio rerio). Dev Comp Immunol. 2020;103 :103523. doi: 10.1016/j.dci.2019.103523. PubMed PMID:31626817 .
4. Talibov, M, Olsson, A, Bailey, H, Erdmann, F, Metayer, C, Magnani, C et al.. Parental occupational exposure to low-frequency magnetic fields and risk of leukaemia in the offspring: findings from the Childhood Leukaemia International Consortium (CLIC). Occup Environ Med. 2019;76 (10):746-753. doi: 10.1136/oemed-2019-105706. PubMed PMID:31358566 PubMed Central PMC6817988.
5. Mehtonen, J, Pölönen, P, Häyrynen, S, Dufva, O, Lin, J, Liuksiala, T et al.. Data-driven characterization of molecular phenotypes across heterogeneous sample collections. Nucleic Acids Res. 2019;47 (13):e76. doi: 10.1093/nar/gkz281. PubMed PMID:31329928 PubMed Central PMC6648337.
6. Heikkilä, P, Kokko, P, Lohi, O, Korppi, M. Nursing intensity scores did not correlate well with reimbursement claims for infant bronchiolitis. Acta Paediatr. 2020;109 (1):140-146. doi: 10.1111/apa.14926. PubMed PMID:31269265 .
7. Pölönen, P, Mehtonen, J, Lin, J, Liuksiala, T, Häyrynen, S, Teppo, S et al.. Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. Cancer Res. 2019;79 (10):2466-2479. doi: 10.1158/0008-5472.CAN-18-2970. PubMed PMID:30940663 .
8. Wolthers, BO, Mogensen, PR, Frandsen, TL, Abrahamsson, J, Behrendtz, M, Heyman, M et al.. Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2019;66 (1):e27437. doi: 10.1002/pbc.27437. PubMed PMID:30216644 .
9. Poukka, M, Lund-Aho, T, Raittinen, P, Nikkilä, A, Kivinen, K, Lundán, T et al.. Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment. J Pediatr Hematol Oncol. 2019;41 (7):e481-e483. doi: 10.1097/MPH.0000000000001267. PubMed PMID:30045148 .

Search PubMed

1. Wolthers, BO, Mogensen, PR, Frandsen, TL, Abrahamsson, J, Behrendtz, M, Heyman, M et al.. Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2019;66 (1):e27437. doi: 10.1002/pbc.27437. PubMed PMID:30216644 .
2. Nikkilä, A, Raitanen, J, Lohi, O, Auvinen, A. Radiation exposure from computerized tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE). Haematologica. 2018;103 (11):1873-1880. doi: 10.3324/haematol.2018.187716. PubMed PMID:29976736 PubMed Central PMC6278981.
3. Nikkilä, A, Kendall, G, Raitanen, J, Spycher, B, Lohi, O, Auvinen, A et al.. Effects of incomplete residential histories on studies of environmental exposure with application to childhood leukaemia and background radiation. Environ Res. 2018;166 :466-472. doi: 10.1016/j.envres.2018.06.035. PubMed PMID:29945121 .
4. Nordfors, K, Haapasalo, J, Afyounian, E, Tuominen, J, Annala, M, Häyrynen, S et al.. Erratum: Whole-exome sequencing identifies germline mutation in and in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. Cold Spring Harb Mol Case Stud. 2018;4 (3):. doi: 10.1101/mcs.a003129. PubMed PMID:29858379 PubMed Central PMC5983177.
5. Nordfors, K, Haapasalo, J, Afyounian, E, Tuominen, J, Annala, M, Häyrynen, S et al.. Whole-exome sequencing identifies germline mutation in and in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. Cold Spring Harb Mol Case Stud. 2018;4 (2):. doi: 10.1101/mcs.a002246. PubMed PMID:29602769 PubMed Central PMC5880256.
6. de Bock, CE, Demeyer, S, Degryse, S, Verbeke, D, Sweron, B, Gielen, O et al.. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. Cancer Discov. 2018;8 (5):616-631. doi: 10.1158/2159-8290.CD-17-0583. PubMed PMID:29496663 .
7. Norberg, A, Rosén, A, Raaschou-Jensen, K, Kjeldsen, L, Moilanen, JS, Paulsson-Karlsson, Y et al.. Novel variants in Nordic patients referred for genetic testing of telomere-related disorders. Eur J Hum Genet. 2018;26 (6):858-867. doi: 10.1038/s41431-018-0112-8. PubMed PMID:29483670 PubMed Central PMC5974393.

Search PubMed

Johanna Mäenpää – Gynaecological oncology

2020-2024

1. Harter, P, Marth, C, Mouret-Reynier, MA, Cropet, C, Lorusso, D, Guerra-Alía, EM et al.. Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial. Ann Oncol. 2024; :. doi: 10.1016/j.annonc.2024.10.828. PubMed PMID:39528049 .
2. Yalew, M, Mulugeta, A, Lumsden, AL, Madakkatel, I, Lee, SH, Oehler, MK et al.. Circulating Phylloquinone and the Risk of Four Female-Specific Cancers: A Mendelian Randomization Study. Nutrients. 2024;16 (21):. doi: 10.3390/nu16213680. PubMed PMID:39519513 PubMed Central PMC11547380.
3. Jirovec, E, Quixabeira, DCA, Clubb, JHA, Pakola, SA, Kudling, T, Arias, V et al.. Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors. J Exp Clin Cancer Res. 2024;43 (1):297. doi: 10.1186/s13046-024-03219-0. PubMed PMID:39506856 PubMed Central PMC11539705.
4. Kivekäs, E, Staff, S, Huhtala, HSA, Mäenpää, JU, Nieminen, K, Tomás, EI et al.. Robotic-assisted versus conventional laparoscopic surgery for endometrial cancer: long-term results of a randomized controlled trial. Am J Obstet Gynecol. 2024; :. doi: 10.1016/j.ajog.2024.08.028. PubMed PMID:39181495 .
5. Madakkatel, I, Lumsden, AL, Mulugeta, A, Mäenpää, J, Oehler, MK, Hyppönen, E et al.. Large-scale analysis to identify risk factors for ovarian cancer. Int J Gynecol Cancer. 2024; :. doi: 10.1136/ijgc-2024-005424. PubMed PMID:39084694 .
6. Mirza, MR, Tandaric, L, Henriksen, JR, Mäenpää, J, Christensen, RD, Waldstrøm, M et al.. NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer. Gynecol Oncol. 2024;188 :103-110. doi: 10.1016/j.ygyno.2024.06.017. PubMed PMID:38943691 .
7. Boidot, R, Blum, MGB, Wissler, MP, Gottin, C, Ruzicka, J, Chevrier, S et al.. Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer. Eur J Cancer. 2024;202 :113978. doi: 10.1016/j.ejca.2024.113978. PubMed PMID:38471290 .
8. Mulugeta, A, Lumsden, AL, Madakkatel, I, Stacey, D, Lee, SH, Mäenpää, J et al.. Phenome-wide association study of ovarian cancer identifies common comorbidities and reveals shared genetics with complex diseases and biomarkers. Cancer Med. 2024;13 (4):e7051. doi: 10.1002/cam4.7051. PubMed PMID:38457211 PubMed Central PMC10923028.
9. Pothuri, B, Han, S, Chase, DM, Heitz, F, Burger, RA, Gaba, L et al.. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial. Gynecol Oncol. 2024;184 :168-177. doi: 10.1016/j.ygyno.2024.01.021. PubMed PMID:38325276 .

Search PubMed

1. Leman, R, Muller, E, Legros, A, Goardon, N, Chentli, I, Atkinson, A et al.. Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer. Clin Cancer Res. 2023;29 (21):4419-4429. doi: 10.1158/1078-0432.CCR-23-0898. PubMed PMID:37756555 PubMed Central PMC10618649.
2. Loverix, L, Vergote, I, Busschaert, P, Vanderstichele, A, Venken, T, Boeckx, B et al.. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial. Eur J Cancer. 2023;188 :131-139. doi: 10.1016/j.ejca.2023.04.020. PubMed PMID:37245441 .
3. Ray-Coquard, I, Leary, A, Pignata, S, Cropet, C, González-Martín, A, Marth, C et al.. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol. 2023;34 (8):681-692. doi: 10.1016/j.annonc.2023.05.005. PubMed PMID:37211045 .
4. Colombo, N, Gadducci, A, Sehouli, J, Rulli, E, Mäenpää, J, Sessa, C et al.. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line. Br J Cancer. 2023;128 (8):1503-1513. doi: 10.1038/s41416-022-02108-7. PubMed PMID:36759720 PubMed Central PMC10070417.

Search PubMed

1. Kristensson, C, Åstrand, A, Donaldson, S, Goldwater, R, Abdulai, R, Patel, N et al.. AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis. J Cyst Fibros. 2022;21 (4):684-690. doi: 10.1016/j.jcf.2022.02.010. PubMed PMID:35227647 .
2. Kirla, KT, Nemes, S, Betts, J, Kristensson, C, Mo, J, Asimus, S et al.. Diurnal variation in DLCO and non-standardized study procedures may cause a false positive safety signal in clinical trials. Respir Med. 2022;191 :106705. doi: 10.1016/j.rmed.2021.106705. PubMed PMID:34879298 .
3. Vergote, I, González-Martín, A, Ray-Coquard, I, Harter, P, Colombo, N, Pujol, P et al.. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. 2022;33 (3):276-287. doi: 10.1016/j.annonc.2021.11.013. PubMed PMID:34861371 .
4. Sadiq, MW, Asimus, S, Belvisi, MG, Brailsford, W, Fransson, R, Fuhr, R et al.. Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease. Br J Clin Pharmacol. 2022;88 (1):260-270. doi: 10.1111/bcp.14956. PubMed PMID:34182611 .

Search PubMed

1. Kirla, KT, Nemes, S, Betts, J, Kristensson, C, Mo, J, Asimus, S et al.. Diurnal variation in DLCO and non-standardized study procedures may cause a false positive safety signal in clinical trials. Respir Med. 2022;191 :106705. doi: 10.1016/j.rmed.2021.106705. PubMed PMID:34879298 .
2. Vergote, I, González-Martín, A, Ray-Coquard, I, Harter, P, Colombo, N, Pujol, P et al.. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. 2022;33 (3):276-287. doi: 10.1016/j.annonc.2021.11.013. PubMed PMID:34861371 .
3. Vergote, I, Ray-Coquard, I, Anderson, DM, Cantuaria, G, Colombo, N, Garnier-Tixidre, C et al.. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer. 2021;157 :415-423. doi: 10.1016/j.ejca.2021.08.023. PubMed PMID:34597975 .
4. Kalamo, M, Mäenpää, J, Seppälä, T, Mecklin, JP, Pylvänäinen, K, Staff, S et al.. Descriptive study on subjective experience of genetic testing with respect to relationship, family planning and psychosocial wellbeing among women with lynch syndrome. Hered Cancer Clin Pract. 2021;19 (1):38. doi: 10.1186/s13053-021-00194-x. PubMed PMID:34521458 PubMed Central PMC8439070.
5. Sadiq, MW, Asimus, S, Belvisi, MG, Brailsford, W, Fransson, R, Fuhr, R et al.. Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease. Br J Clin Pharmacol. 2022;88 (1):260-270. doi: 10.1111/bcp.14956. PubMed PMID:34182611 .
6. Moore, KN, Bookman, M, Sehouli, J, Miller, A, Anderson, C, Scambia, G et al.. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021;39 (17):1842-1855. doi: 10.1200/JCO.21.00306. PubMed PMID:33891472 PubMed Central PMC8189598.
7. Callens, C, Vaur, D, Soubeyran, I, Rouleau, E, Just, PA, Guillerm, E et al.. Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. J Natl Cancer Inst. 2021;113 (7):917-923. doi: 10.1093/jnci/djaa193. PubMed PMID:33372675 PubMed Central PMC8246800.
8. Veijalainen, O, Kares, S, Kotaniemi-Talonen, L, Kujala, P, Vuento, R, Luukkaala, T et al.. Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland. Acta Obstet Gynecol Scand. 2021;100 (3):403-409. doi: 10.1111/aogs.14021. PubMed PMID:33037625 .

Search PubMed

1. Jäntti, T, Luhtala, S, Mäenpää, J, Staff, S. Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer. Tumour Biol. 2020;42 (11):1010428320971404. doi: 10.1177/1010428320971404. PubMed PMID:33169632 .
2. Veijalainen, O, Kares, S, Kotaniemi-Talonen, L, Kujala, P, Vuento, R, Luukkaala, T et al.. Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland. Acta Obstet Gynecol Scand. 2021;100 (3):403-409. doi: 10.1111/aogs.14021. PubMed PMID:33037625 .
3. Savolainen, K, Scaravilli, M, Ilvesmäki, A, Staff, S, Tolonen, T, Mäenpää, JU et al.. Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts. BMC Res Notes. 2020;13 (1):311. doi: 10.1186/s13104-020-05155-6. PubMed PMID:32611374 PubMed Central PMC7329467.
4. Kuittinen, T, Rovio, P, Luukkaala, T, Laurila, M, Grénman, S, Kallioniemi, A et al.. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells . Anticancer Res. 2020;40 (6):3129-3138. doi: 10.21873/anticanres.14294. PubMed PMID:32487607 .
5. Huttala, O, Staff, S, Heinonen, T, Mäenpää, J, Tanner, M, Ylikomi, T et al.. In Vitro Vascular Network Modified to Function as Culture Platform and Angiogenic Induction Potential Test for Cancer Cells. Int J Mol Sci. 2020;21 (5):. doi: 10.3390/ijms21051833. PubMed PMID:32155897 PubMed Central PMC7084873.
6. Rohr, I, Alavi, S, Richter, R, Keller, M, Chekerov, R, Oskay-Özcelik, G et al.. Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV). Int J Gynecol Cancer. 2020;30 (4):509-514. doi: 10.1136/ijgc-2019-000892. PubMed PMID:32139438 .
7. Aalto, A, Huotari-Orava, R, Luhtala, S, Mäenpää, J, Staff, S. Expression of Estrogen-Related Receptors in Localized Provoked Vulvodynia. Biores Open Access. 2020;9 (1):13-21. doi: 10.1089/biores.2019.0049. PubMed PMID:32117596 PubMed Central PMC7047250.
8. Kalamo, MH, Mäenpää, JU, Seppälä, TT, Mecklin, JP, Huhtala, H, Sorvettula, K et al.. Factors associated with decision-making on prophylactic hysterectomy and attitudes towards gynecological surveillance among women with Lynch syndrome (LS): a descriptive study. Fam Cancer. 2020;19 (2):177-182. doi: 10.1007/s10689-020-00158-5. PubMed PMID:31997047 PubMed Central PMC7101284.
9. Vuorinen, RK, Luukkaala, TH, Mäenpää, JU. The influence of bevacizumab on the costs of ovarian cancer treatment in routine clinical practice. Acta Oncol. 2020;59 (4):453-457. doi: 10.1080/0284186X.2019.1711175. PubMed PMID:31920123 .
10. Antila, RM, Mäenpää, JU, Huhtala, HS, Tomás, EI, Staff, SM. Association of cesarean scar defect with abnormal uterine bleeding: The results of a prospective study. Eur J Obstet Gynecol Reprod Biol. 2020;244 :134-140. doi: 10.1016/j.ejogrb.2019.11.021. PubMed PMID:31785470 .

Search PubMed

1. Ray-Coquard, I, Pautier, P, Pignata, S, Pérol, D, González-Martín, A, Berger, R et al.. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381 (25):2416-2428. doi: 10.1056/NEJMoa1911361. PubMed PMID:31851799 .
2. Antila, RM, Mäenpää, JU, Huhtala, HS, Tomás, EI, Staff, SM. Association of cesarean scar defect with abnormal uterine bleeding: The results of a prospective study. Eur J Obstet Gynecol Reprod Biol. 2020;244 :134-140. doi: 10.1016/j.ejogrb.2019.11.021. PubMed PMID:31785470 .
3. González-Martín, A, Pothuri, B, Vergote, I, DePont Christensen, R, Graybill, W, Mirza, MR et al.. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381 (25):2391-2402. doi: 10.1056/NEJMoa1910962. PubMed PMID:31562799 .
4. Mirza, MR, Åvall Lundqvist, E, Birrer, MJ, dePont Christensen, R, Nyvang, GB, Malander, S et al.. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019;20 (10):1409-1419. doi: 10.1016/S1470-2045(19)30515-7. PubMed PMID:31474354 .
5. Kares, S, Veijalainen, O, Kholová, I, Tirkkonen, M, Vuento, R, Huhtala, H et al.. HIGH-RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping?. APMIS. 2019;127 (11):710-716. doi: 10.1111/apm.12990. PubMed PMID:31403733 .
6. Mirza, MR, Bergmann, TK, Mau-Sørensen, M, Christensen, RD, Åvall-Lundqvist, E, Birrer, MJ et al.. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemother Pharmacol. 2019;84 (4):791-798. doi: 10.1007/s00280-019-03917-z. PubMed PMID:31375879 .
7. Falconer, H, Palsdottir, K, Stalberg, K, Dahm-Kähler, P, Ottander, U, Lundin, ES et al.. Robot-assisted approach to cervical cancer (RACC): an international multi-center, open-label randomized controlled trial. Int J Gynecol Cancer. 2019;29 (6):1072-1076. doi: 10.1136/ijgc-2019-000558. PubMed PMID:31203203 .
8. Aalto, AP, Huhtala, H, Mäenpää, J, Staff, S. Combination of Treatments With or Without Surgery in Localized Provoked Vulvodynia: Outcomes After Three Years of Follow-Up. Biores Open Access. 2019;8 (1):25-31. doi: 10.1089/biores.2018.0044. PubMed PMID:30867980 PubMed Central PMC6415354.
9. Bhatla, N, Berek, JS, Cuello Fredes, M, Denny, LA, Grenman, S, Karunaratne, K et al.. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019;145 (1):129-135. doi: 10.1002/ijgo.12749. PubMed PMID:30656645 .
10. Lagerstedt, M, Huotari-Orava, R, Nyberg, R, Nissinen, L, Farshchian, M, Laasanen, SL et al.. Tumor cell-specific Serpin A1 expression in vulvar squamous cell carcinoma. Arch Gynecol Obstet. 2019;299 (5):1345-1351. doi: 10.1007/s00404-018-5015-y. PubMed PMID:30607583 PubMed Central PMC6475512.
11. Veijalainen, O, Kares, S, Kujala, P, Vuento, R, Osuala, V, Tirkkonen, M et al.. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience. Cytopathology. 2019;30 (2):150-156. doi: 10.1111/cyt.12652. PubMed PMID:30421573 .

Search PubMed

1. Veijalainen, O, Kares, S, Kujala, P, Vuento, R, Osuala, V, Tirkkonen, M et al.. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience. Cytopathology. 2019;30 (2):150-156. doi: 10.1111/cyt.12652. PubMed PMID:30421573 .
2. Niemi, RJ, Braicu, EI, Kulbe, H, Koistinen, KM, Sehouli, J, Puistola, U et al.. Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism. Br J Cancer. 2018;119 (7):847-854. doi: 10.1038/s41416-018-0270-z. PubMed PMID:30293997 PubMed Central PMC6189177.
3. Niemi, RJ, Roine, AN, Eräviita, E, Kumpulainen, PS, Mäenpää, JU, Oksala, N et al.. FAIMS analysis of urine gaseous headspace is capable of differentiating ovarian cancer. Gynecol Oncol. 2018;151 (3):519-524. doi: 10.1016/j.ygyno.2018.09.016. PubMed PMID:30257785 .
4. Antila-Långsjö, RM, Mäenpää, JU, Huhtala, HS, Tomás, EI, Staff, SM. Cesarean scar defect: a prospective study on risk factors. Am J Obstet Gynecol. 2018;219 (5):458.e1-458.e8. doi: 10.1016/j.ajog.2018.09.004. PubMed PMID:30240650 .
5. Veskimäe, K, Scaravilli, M, Niininen, W, Karvonen, H, Jaatinen, S, Nykter, M et al.. Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies. Transl Oncol. 2018;11 (5):1160-1170. doi: 10.1016/j.tranon.2018.07.010. PubMed PMID:30056367 PubMed Central PMC6079561.
6. Antila-Långsjö, R, Mäenpää, JU, Huhtala, H, Tomás, E, Staff, S. Comparison of transvaginal ultrasound and saline contrast sonohysterography in evaluation of cesarean scar defect: a prospective cohort study. Acta Obstet Gynecol Scand. 2018;97 (9):1130-1136. doi: 10.1111/aogs.13367. PubMed PMID:29754409 .
7. Mäenpää, MM, Nieminen, K, Tomás, EI, Luukkaala, TH, Mäenpää, JU. Robotic-Assisted Infrarenal Para-aortic Lymphadenectomy in Gynecological Cancers: Technique and Surgical Outcomes. Int J Gynecol Cancer. 2018;28 (5):951-958. doi: 10.1097/IGC.0000000000001249. PubMed PMID:29683877 .
8. Palmér, R, Mäenpää, J, Jauhiainen, A, Larsson, B, Mo, J, Russell, M et al.. Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a Sustained, Exposure-Dependent Reduction in Neutrophil Elastase Activity in Healthy Subjects. Clin Pharmacol Ther. 2018;104 (6):1155-1164. doi: 10.1002/cpt.1053. PubMed PMID:29484635 PubMed Central PMC6282495.

Search PubMed

Daniela Ungureanu – Cancer Signalling

2020-2024

1. Dini, A, Barker, H, Piki, E, Sharma, S, Raivola, J, Murumägi, A et al.. A multiplex single-cell RNA-Seq pharmacotranscriptomics pipeline for drug discovery. Nat Chem Biol. 2024; :. doi: 10.1038/s41589-024-01761-8. PubMed PMID:39482470 .

Search PubMed

1. Piki, E, Dini, A, Raivola, J, Salokas, K, Zhang, K, Varjosalo, M et al.. ROR1-STAT3 signaling contributes to ovarian cancer intra-tumor heterogeneity. Cell Death Discov. 2023;9 (1):222. doi: 10.1038/s41420-023-01527-6. PubMed PMID:37400436 PubMed Central PMC10317980.
2. Murumägi, A, Ungureanu, D, Khan, S, Arjama, M, Välimäki, K, Ianevski, A et al.. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma. Br J Cancer. 2023;128 (4):678-690. doi: 10.1038/s41416-022-02067-z. PubMed PMID:36476658 PubMed Central PMC9938120.

Search PubMed

1. Murumägi, A, Ungureanu, D, Khan, S, Arjama, M, Välimäki, K, Ianevski, A et al.. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma. Br J Cancer. 2023;128 (4):678-690. doi: 10.1038/s41416-022-02067-z. PubMed PMID:36476658 PubMed Central PMC9938120.
2. Raivola, J, Dini, A, Karvonen, H, Piki, E, Salokas, K, Niininen, W et al.. Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention. Cell Death Dis. 2022;13 (8):714. doi: 10.1038/s41419-022-05161-5. PubMed PMID:35977930 PubMed Central PMC9386025.
3. Karvonen, H, Raivola, J, Ungureanu, D. Cellular thermal shift assay (CETSA) for determining the drug binding affinity using Ba/F3 clones stably expressing receptor pseudokinases. Methods Enzymol. 2022;667 :339-363. doi: 10.1016/bs.mie.2022.03.038. PubMed PMID:35525546 .
4. Raivola, J, Dini, A, Salokas, K, Karvonen, H, Niininen, W, Piki, E et al.. New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome. Cell Mol Life Sci. 2022;79 (5):276. doi: 10.1007/s00018-022-04301-6. PubMed PMID:35504983 PubMed Central PMC9064840.
5. Kohtamäki, L, Arjama, M, Mäkelä, S, Ianevski, P, Välimäki, K, Juteau, S et al.. High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. Transl Oncol. 2022;15 (1):101290. doi: 10.1016/j.tranon.2021.101290. PubMed PMID:34837846 PubMed Central PMC8633005.

Search PubMed

1. Kohtamäki, L, Arjama, M, Mäkelä, S, Ianevski, P, Välimäki, K, Juteau, S et al.. High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. Transl Oncol. 2022;15 (1):101290. doi: 10.1016/j.tranon.2021.101290. PubMed PMID:34837846 PubMed Central PMC8633005.
2. Jacome Sanz, D, Raivola, J, Karvonen, H, Arjama, M, Barker, H, Murumägi, A et al.. Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors. Cancers (Basel). 2021;13 (15):. doi: 10.3390/cancers13153727. PubMed PMID:34359627 PubMed Central PMC8345177.
3. Murumägi, A, Ungureanu, D, Arjama, M, Bützow, R, Lohi, J, Sariola, H et al.. STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells. Transl Oncol. 2021;14 (4):101027. doi: 10.1016/j.tranon.2021.101027. PubMed PMID:33530027 PubMed Central PMC7851186.

Search PubMed

1. Karvonen, H, Arjama, M, Kaleva, L, Niininen, W, Barker, H, Koivisto-Korander, R et al.. Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. Cell Death Dis. 2020;11 (9):790. doi: 10.1038/s41419-020-03009-4. PubMed PMID:32989221 PubMed Central PMC7522257.
2. Sheetz, JB, Mathea, S, Karvonen, H, Malhotra, K, Chatterjee, D, Niininen, W et al.. Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. Mol Cell. 2020;79 (3):390-405.e7. doi: 10.1016/j.molcel.2020.06.018. PubMed PMID:32619402 PubMed Central PMC7543951.

Search PubMed

1. Karvonen, H, Barker, H, Kaleva, L, Niininen, W, Ungureanu, D. Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways. Cells. 2019;8 (8):. doi: 10.3390/cells8080812. PubMed PMID:31382410 PubMed Central PMC6721603.
2. Tudor, Ș, Minciună, C, Lăcătuş, M, Gavrilă, D, Manciu, S, Ungureanu, D et al.. Transanal Total Mesorectal Excision – A Case Report. Chirurgia (Bucur). 2019;114 (2):278-283. doi: 10.21614/chirurgia.114.2.278. PubMed PMID:31060661 .
3. Karvonen, H, Perttilä, R, Niininen, W, Hautanen, V, Barker, H, Murumägi, A et al.. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting. Oncogene. 2019;38 (17):3288-3300. doi: 10.1038/s41388-018-0670-9. PubMed PMID:30631148 .

Search PubMed

1. Karvonen, H, Perttilä, R, Niininen, W, Barker, H, Ungureanu, D. Targeting Wnt signaling pseudokinases in hematological cancers. Eur J Haematol. 2018;101 (4):457-465. doi: 10.1111/ejh.13137. PubMed PMID:29989208 .
2. Karvonen, H, Summala, K, Niininen, W, Barker, HR, Ungureanu, D. Interaction between ROR1 and MuSK activation complex in myogenic cells. FEBS Lett. 2018;592 (3):434-445. doi: 10.1002/1873-3468.12966. PubMed PMID:29292499 .

Search PubMed

Tapio Visakorpi (Teuvo Tammela) – Molecular Biology of Prostate Cancer

2020-2024

1. Kiviaho, A, Eerola, SK, Kallio, HML, Andersen, MK, Hoikka, M, Tiihonen, AM et al.. Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. Nat Commun. 2024;15 (1):9949. doi: 10.1038/s41467-024-54364-1. PubMed PMID:39550375 PubMed Central PMC11569175.
2. Lawlor, A, Beyer, K, Russell, B, Steinbeisser, C, Bjartell, A, De Meulder, B et al.. PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research. Nat Rev Urol. 2024; :. doi: 10.1038/s41585-024-00925-4. PubMed PMID:39251785 .
3. Kohvakka, A, Sattari, M, Nättinen, J, Aapola, U, Gregorová, P, Tammela, TLJ et al.. Long noncoding RNA EPCART regulates translation through PI3K/AKT/mTOR pathway and PDCD4 in prostate cancer. Cancer Gene Ther. 2024;31 (10):1536-1546. doi: 10.1038/s41417-024-00822-3. PubMed PMID:39147845 PubMed Central PMC11489079.
4. Olotu, O, Koskenniemi, AR, Ma, L, Paramonov, V, Laasanen, S, Louramo, E et al.. Germline-specific RNA helicase DDX4 forms cytoplasmic granules in cancer cells and promotes tumor growth. Cell Rep. 2024;43 (7):114430. doi: 10.1016/j.celrep.2024.114430. PubMed PMID:38963760 .
5. Russell, B, Beyer, K, Lawlor, A, Roobol, MJ, Venderbos, LDF, Remmers, S et al.. Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?. Eur Urol Open Sci. 2024;59 :27-29. doi: 10.1016/j.euros.2023.11.004. PubMed PMID:38298764 PubMed Central PMC10829596.

Search PubMed

1. Russell, B, Beyer, K, Lawlor, A, Roobol, MJ, Venderbos, LDF, Remmers, S et al.. Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?. Eur Urol Open Sci. 2024;59 :27-29. doi: 10.1016/j.euros.2023.11.004. PubMed PMID:38298764 PubMed Central PMC10829596.
2. Nurminen, A, Jaatinen, S, Taavitsainen, S, Högnäs, G, Lesluyes, T, Ansari-Pour, N et al.. Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine. Genome Med. 2023;15 (1):82. doi: 10.1186/s13073-023-01242-y. PubMed PMID:37828555 PubMed Central PMC10571458.
3. Sattari, M, Kohvakka, A, Moradi, E, Rauhala, H, Urhonen, H, Isaacs, WB et al.. Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases. Endocr Relat Cancer. 2023;30 (8):. doi: 10.1530/ERC-22-0247. PubMed PMID:37140987 PubMed Central PMC10326635.
4. Omar, MI, MacLennan, S, Ribal, MJ, Roobol, MJ, Dimitropoulos, K, van den Broeck, T et al.. Unanswered questions in prostate cancer – findings of an international multi-stakeholder consensus by the PIONEER consortium. Nat Rev Urol. 2023;20 (8):494-501. doi: 10.1038/s41585-023-00748-9. PubMed PMID:37012441 .
5. Yakneen, S, Waszak, SM, PCAWG Technical Working Group, Gertz, M, Korbel, JO, PCAWG Consortium et al.. Author Correction: Butler enables rapid cloud-based analysis of thousands of human genomes. Nat Biotechnol. 2023;41 (4):577. doi: 10.1038/s41587-022-01554-1. PubMed PMID:36944844 PubMed Central PMC10110458.
6. Rodriguez-Martin, B, Alvarez, EG, Baez-Ortega, A, Zamora, J, Supek, F, Demeulemeester, J et al.. Author Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet. 2023;55 (6):1080. doi: 10.1038/s41588-023-01319-9. PubMed PMID:36944736 PubMed Central PMC10260396.
7. Akdemir, KC, Le, VT, Chandran, S, Li, Y, Verhaak, RG, Beroukhim, R et al.. Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet. 2023;55 (6):1079. doi: 10.1038/s41588-023-01318-w. PubMed PMID:36944735 PubMed Central PMC10260394.
8. Zapatka, M, Borozan, I, Brewer, DS, Iskar, M, Grundhoff, A, Alawi, M et al.. Author Correction: The landscape of viral associations in human cancers. Nat Genet. 2023;55 (6):1077. doi: 10.1038/s41588-023-01316-y. PubMed PMID:36944734 PubMed Central PMC10260395.
9. Cortés-Ciriano, I, Lee, JJ, Xi, R, Jain, D, Jung, YL, Yang, L et al.. Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. 2023;55 (6):1076. doi: 10.1038/s41588-023-01315-z. PubMed PMID:36944733 PubMed Central PMC10260391.
10. Yuan, Y, Ju, YS, Kim, Y, Li, J, Wang, Y, Yoon, CJ et al.. Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet. 2023;55 (6):1078. doi: 10.1038/s41588-023-01317-x. PubMed PMID:36944732 PubMed Central PMC10260393.
11. Alexandrov, LB, Kim, J, Haradhvala, NJ, Huang, MN, Tian Ng, AW, Wu, Y et al.. Author Correction: The repertoire of mutational signatures in human cancer. Nature. 2023;614 (7948):E41. doi: 10.1038/s41586-022-05600-5. PubMed PMID:36697836 PubMed Central PMC9931578.
12. Li, Y, Roberts, ND, Wala, JA, Shapira, O, Schumacher, SE, Kumar, K et al.. Author Correction: Patterns of somatic structural variation in human cancer genomes. Nature. 2023;614 (7948):E38. doi: 10.1038/s41586-022-05597-x. PubMed PMID:36697835 PubMed Central PMC9931568.
13. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Author Correction: Pan-cancer analysis of whole genomes. Nature. 2023;614 (7948):E39. doi: 10.1038/s41586-022-05598-w. PubMed PMID:36697834 PubMed Central PMC9931570.
14. Gerstung, M, Jolly, C, Leshchiner, I, Dentro, SC, Gonzalez, S, Rosebrock, D et al.. Author Correction: The evolutionary history of 2,658 cancers. Nature. 2023;614 (7948):E42. doi: 10.1038/s41586-022-05601-4. PubMed PMID:36697833 PubMed Central PMC9931577.
15. Rheinbay, E, Nielsen, MM, Abascal, F, Wala, JA, Shapira, O, Tiao, G et al.. Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2023;614 (7948):E40. doi: 10.1038/s41586-022-05599-9. PubMed PMID:36697832 PubMed Central PMC9931557.
16. PCAWG Transcriptome Core Group, Calabrese, C, Davidson, NR, Demircioğlu, D, Fonseca, NA, He, Y et al.. Author Correction: Genomic basis for RNA alterations in cancer. Nature. 2023;614 (7948):E37. doi: 10.1038/s41586-022-05596-y. PubMed PMID:36697831 PubMed Central PMC9931574.
17. Siltari, A, Lönnerbro, R, Pang, K, Shiranov, K, Asiimwe, A, Evans-Axelsson, S et al.. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2023;21 (2):316.e1-316.e11. doi: 10.1016/j.clgc.2022.09.006. PubMed PMID:36243664 .

Search PubMed

1. Bögemann, M, Shore, ND, Smith, MR, Tammela, TLJ, Ulys, A, Vjaters, E et al.. Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022]. Eur Urol. 2023;83 (2):e60. doi: 10.1016/j.eururo.2022.11.018. PubMed PMID:36526492 .
2. Carlevaro-Fita, J, Lanzós, A, Feuerbach, L, Hong, C, Mas-Ponte, D, Pedersen, JS et al.. Author Correction: Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol. 2022;5 (1):1347. doi: 10.1038/s42003-022-03769-z. PubMed PMID:36482178 PubMed Central PMC9732278.
3. Rubanova, Y, Shi, R, Harrigan, CF, Li, R, Wintersinger, J, Sahin, N et al.. Author Correction: Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nat Commun. 2022;13 (1):7567. doi: 10.1038/s41467-022-32336-7. PubMed PMID:36482170 PubMed Central PMC9731941.
4. Sieverling, L, Hong, C, Koser, SD, Ginsbach, P, Kleinheinz, K, Hutter, B et al.. Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun. 2022;13 (1):7574. doi: 10.1038/s41467-022-32328-7. PubMed PMID:36481818 PubMed Central PMC9731961.
5. Shuai, S, PCAWG Drivers and Functional Interpretation Working Group, Gallinger, S, Stein, LD, PCAWG Consortium. Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nat Commun. 2022;13 (1):7571. doi: 10.1038/s41467-022-32343-8. PubMed PMID:36481739 PubMed Central PMC9732291.
6. Cmero, M, Yuan, K, Ong, CS, Schröder, J, PCAWG Evolution and Heterogeneity Working Group, Corcoran, NM et al.. Author Correction: Inferring structural variant cancer cell fraction. Nat Commun. 2022;13 (1):7568. doi: 10.1038/s41467-022-32338-5. PubMed PMID:36481724 PubMed Central PMC9732297.
7. Jiao, W, Atwal, G, Polak, P, Karlic, R, Cuppen, E, PCAWG Tumor Subtypes and Clinical Translation Working Group et al.. Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun. 2022;13 (1):7573. doi: 10.1038/s41467-022-32329-6. PubMed PMID:36481665 PubMed Central PMC9732335.
8. Paczkowska, M, Barenboim, J, Sintupisut, N, Fox, NS, Zhu, H, Abd-Rabbo, D et al.. Author Correction: Integrative pathway enrichment analysis of multivariate omics data. Nat Commun. 2022;13 (1):7570. doi: 10.1038/s41467-022-32342-9. PubMed PMID:36481658 PubMed Central PMC9731958.
9. Zhang, Y, Chen, F, Fonseca, NA, He, Y, Fujita, M, Nakagawa, H et al.. Author Correction: High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. Nat Commun. 2022;13 (1):7572. doi: 10.1038/s41467-022-32333-w. PubMed PMID:36481652 PubMed Central PMC9732340.
10. Bhandari, V, Li, CH, Bristow, RG, Boutros, PC, PCAWG Consortium. Author Correction: Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun. 2022;13 (1):7569. doi: 10.1038/s41467-022-32339-4. PubMed PMID:36481612 PubMed Central PMC9731962.
11. Reyna, MA, Haan, D, Paczkowska, M, Verbeke, LPC, Vazquez, M, Kahraman, A et al.. Author Correction: Pathway and network analysis of more than 2500 whole cancer genomes. Nat Commun. 2022;13 (1):7566. doi: 10.1038/s41467-022-32334-9. PubMed PMID:36481610 PubMed Central PMC9732045.
12. Nygård, LH, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia. Prostate. 2023;83 (3):246-258. doi: 10.1002/pros.24456. PubMed PMID:36325820 .
13. Bernard, D, Martinez-Leal, JF, Rizzo, S, Martinez, D, Hudson, D, Visakorpi, T et al.. Retraction Note: CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene. 2022;41 (45):4980. doi: 10.1038/s41388-022-02502-8. PubMed PMID:36253447 .
14. Siltari, A, Lönnerbro, R, Pang, K, Shiranov, K, Asiimwe, A, Evans-Axelsson, S et al.. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2023;21 (2):316.e1-316.e11. doi: 10.1016/j.clgc.2022.09.006. PubMed PMID:36243664 .
15. Kukkonen, K, Autio-Kimura, B, Rauhala, H, Kesseli, J, Nykter, M, Latonen, L et al.. Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen. Endocr Relat Cancer. 2022;29 (12):717-733. doi: 10.1530/ERC-22-0108. PubMed PMID:36219867 PubMed Central PMC9644224.
16. Buhigas, C, Warren, AY, Leung, WK, Whitaker, HC, Luxton, HJ, Hawkins, S et al.. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates. Mol Cancer. 2022;21 (1):183. doi: 10.1186/s12943-022-01644-3. PubMed PMID:36131292 PubMed Central PMC9494848.
17. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and prostate cancer survival in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2024;27 (1):73-80. doi: 10.1038/s41391-022-00597-4. PubMed PMID:36131010 PubMed Central PMC10876474.
18. Bögemann, M, Shore, ND, Smith, MR, Tammela, TLJ, Ulys, A, Vjaters, E et al.. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial. Eur Urol. 2023;83 (3):212-221. doi: 10.1016/j.eururo.2022.07.018. PubMed PMID:36089529 .
19. Peltomaa, AI, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level. Cancers (Basel). 2022;14 (12):. doi: 10.3390/cancers14122920. PubMed PMID:35740586 PubMed Central PMC9221017.
20. Salminen, JK, Mehtola, A, Talala, K, Taari, K, Mäkinen, J, Peltola, J et al.. Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer. Br J Cancer. 2022;127 (4):704-711. doi: 10.1038/s41416-022-01817-3. PubMed PMID:35505251 PubMed Central PMC9381528.
21. Åkerla, J, Pesonen, JS, Pöyhönen, A, Koskimäki, J, Häkkinen, J, Huhtala, H et al.. Lower Urinary Tract Symptoms and Mortality among Finnish Men: The Roles of Symptom Severity and Bother. J Urol. 2022;207 (6):1285-1294. doi: 10.1097/JU.0000000000002450. PubMed PMID:35470712 .
22. Scaravilli, M, Koivukoski, S, Gillen, A, Bouazza, A, Ruusuvuori, P, Visakorpi, T et al.. miR-32 promotes MYC-driven prostate cancer. Oncogenesis. 2022;11 (1):11. doi: 10.1038/s41389-022-00385-8. PubMed PMID:35228520 PubMed Central PMC8885642.
23. Smith, MR, Hussain, M, Saad, F, Fizazi, K, Sternberg, CN, Crawford, ED et al.. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386 (12):1132-1142. doi: 10.1056/NEJMoa2119115. PubMed PMID:35179323 PubMed Central PMC9844551.
24. Jeyapala, R, Kamdar, S, Olkhov-Mitsel, E, Zlotta, A, Fleshner, N, Visakorpi, T et al.. Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients. Clin Genitourin Cancer. 2022;20 (3):e217-e226. doi: 10.1016/j.clgc.2022.01.003. PubMed PMID:35151601 .
25. Ruusuvuori, P, Valkonen, M, Kartasalo, K, Valkonen, M, Visakorpi, T, Nykter, M et al.. Spatial analysis of histology in 3D: quantification and visualization of organ and tumor level tissue environment. Heliyon. 2022;8 (1):e08762. doi: 10.1016/j.heliyon.2022.e08762. PubMed PMID:35128089 PubMed Central PMC8800033.
26. Eskelinen, T, Veitonmäki, T, Kotsar, A, Tammela, TLJ, Pöyhönen, A, Murtola, TJ et al.. Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system. Cancer Causes Control. 2022;33 (2):313-320. doi: 10.1007/s10552-021-01527-w. PubMed PMID:34921656 PubMed Central PMC8776666.
27. Vettenranta, A, Murtola, TJ, Raitanen, J, Raittinen, P, Talala, K, Taari, K et al.. Outcomes of Screening for Prostate Cancer Among Men Who Use Statins. JAMA Oncol. 2022;8 (1):61-68. doi: 10.1001/jamaoncol.2021.5672. PubMed PMID:34817559 PubMed Central PMC8777566.
28. Pöyhönen, A, Åkerla, J, Koskimäki, J, Tammela, TLJ, Auvinen, A. Sauna habits/bathing and changes in lower urinary tract symptoms – Tampere Ageing Male Urologic Study (TAMUS). Scand J Urol. 2022;56 (1):77-82. doi: 10.1080/21681805.2021.2002403. PubMed PMID:34783288 .

Search PubMed

1. Eskelinen, T, Veitonmäki, T, Kotsar, A, Tammela, TLJ, Pöyhönen, A, Murtola, TJ et al.. Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system. Cancer Causes Control. 2022;33 (2):313-320. doi: 10.1007/s10552-021-01527-w. PubMed PMID:34921656 PubMed Central PMC8776666.
2. Pöyhönen, A, Åkerla, J, Koskimäki, J, Tammela, TLJ, Auvinen, A. Sauna habits/bathing and changes in lower urinary tract symptoms – Tampere Ageing Male Urologic Study (TAMUS). Scand J Urol. 2022;56 (1):77-82. doi: 10.1080/21681805.2021.2002403. PubMed PMID:34783288 .
3. Beyer, K, MacLennan, SJ, Moris, L, Lardas, M, Mastris, K, Hooker, G et al.. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. Eur Urol Focus. 2021;7 (5):943-946. doi: 10.1016/j.euf.2021.09.008. PubMed PMID:34602368 .
4. Taavitsainen, S, Engedal, N, Cao, S, Handle, F, Erickson, A, Prekovic, S et al.. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nat Commun. 2021;12 (1):5307. doi: 10.1038/s41467-021-25624-1. PubMed PMID:34489465 PubMed Central PMC8421417.
5. Raittinen, PVH, Syvälä, H, Tammela, TLJ, Häkkinen, MR, Ilmonen, P, Auriola, S et al.. Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial. EBioMedicine. 2021;68 :103432. doi: 10.1016/j.ebiom.2021.103432. PubMed PMID:34144486 PubMed Central PMC8219992.
6. Launonen, KM, Paakinaho, V, Sigismondo, G, Malinen, M, Sironen, R, Hartikainen, JM et al.. Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells. Oncogene. 2021;40 (27):4567-4579. doi: 10.1038/s41388-021-01887-2. PubMed PMID:34127815 PubMed Central PMC8266679.
7. Sipeky, C, Tammela, TLJ, Auvinen, A, Schleutker, J. Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease. Prostate Cancer Prostatic Dis. 2021;24 (4):1158-1166. doi: 10.1038/s41391-021-00378-5. PubMed PMID:34012061 PubMed Central PMC8616752.
8. Eerola, SK, Kohvakka, A, Tammela, TLJ, Koskinen, PJ, Latonen, L, Visakorpi, T et al.. Expression and ERG regulation of PIM kinases in prostate cancer. Cancer Med. 2021;10 (10):3427-3436. doi: 10.1002/cam4.3893. PubMed PMID:33932111 PubMed Central PMC8124112.
9. Vettenranta, A, Murtola, TJ, Talala, K, Taari, K, Stenman, UH, Tammela, TLJ et al.. Outcomes of prostate cancer screening among men using antidiabetic medication. Sci Rep. 2021;11 (1):7363. doi: 10.1038/s41598-021-86534-2. PubMed PMID:33795720 PubMed Central PMC8016840.
10. Peltomaa, AI, Raittinen, P, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study. Prostate Cancer Prostatic Dis. 2021;24 (3):917-924. doi: 10.1038/s41391-021-00351-2. PubMed PMID:33790420 PubMed Central PMC8384625.
11. Vihervuori, VJ, Talala, K, Taari, K, Lahtela, J, Tammela, TLJ, Auvinen, A et al.. Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort. Cancer Epidemiol Biomarkers Prev. 2021;30 (5):982-989. doi: 10.1158/1055-9965.EPI-19-0580. PubMed PMID:33653815 .
12. Salminen, JK, Kuoppamäki, V, Talala, K, Taari, K, Mäkinen, J, Peltola, J et al.. Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Int J Cancer. 2021;149 (2):307-315. doi: 10.1002/ijc.33535. PubMed PMID:33634851 .
13. Beyer, K, Moris, L, Lardas, M, Haire, A, Barletta, F, Scuderi, S et al.. Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. BMJ Open. 2021;11 (2):e040531. doi: 10.1136/bmjopen-2020-040531. PubMed PMID:33574142 PubMed Central PMC7880102.
14. Neupane, S, Nevalainen, J, Raitanen, J, Talala, K, Kujala, P, Taari, K et al.. Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation. Cancers (Basel). 2021;13 (3):. doi: 10.3390/cancers13030435. PubMed PMID:33498854 PubMed Central PMC7865328.
15. Conti, DV, Darst, BF, Moss, LC, Saunders, EJ, Sheng, X, Chou, A et al.. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021;53 (3):413. doi: 10.1038/s41588-021-00786-2. PubMed PMID:33473200 .
16. Karlsson, Q, Brook, MN, Dadaev, T, Wakerell, S, Saunders, EJ, Muir, K et al.. Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. Eur Urol Oncol. 2021;4 (4):570-579. doi: 10.1016/j.euo.2020.12.001. PubMed PMID:33436325 PubMed Central PMC8381233.
17. Conti, DV, Darst, BF, Moss, LC, Saunders, EJ, Sheng, X, Chou, A et al.. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021;53 (1):65-75. doi: 10.1038/s41588-020-00748-0. PubMed PMID:33398198 PubMed Central PMC8148035.
18. Pakarainen, T, Nevalainen, J, Talala, K, Taari, K, Raitanen, J, Kujala, P et al.. Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). Cancer. 2021;127 (2):188-192. doi: 10.1002/cncr.33254. PubMed PMID:33048394 .
19. Pöyhönen, A, Åkerla, J, Koskimäki, J, Tammela, TLJ, Auvinen, A. Seasonal changes in occurrence and severity of lower urinary tract symptoms-Tampere Aging Male Urologic Study (TAMUS). Low Urin Tract Symptoms. 2021;13 (2):216-223. doi: 10.1111/luts.12353. PubMed PMID:33034153 .

Search PubMed

1. Bailey, MH, Meyerson, WU, Dursi, LJ, Wang, LB, Dong, G, Liang, WW et al.. Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun. 2020;11 (1):6232. doi: 10.1038/s41467-020-20128-w. PubMed PMID:33257764 PubMed Central PMC7705717.
2. Sipeky, C, Talala, KM, Tammela, TLJ, Taari, K, Auvinen, A, Schleutker, J et al.. Prostate cancer risk prediction using a polygenic risk score. Sci Rep. 2020;10 (1):17075. doi: 10.1038/s41598-020-74172-z. PubMed PMID:33051487 PubMed Central PMC7553910.
3. Pakarainen, T, Nevalainen, J, Talala, K, Taari, K, Raitanen, J, Kujala, P et al.. Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). Cancer. 2021;127 (2):188-192. doi: 10.1002/cncr.33254. PubMed PMID:33048394 .
4. Hietikko, R, Kilpeläinen, TP, Kenttämies, A, Ronkainen, J, Ijäs, K, Lind, K et al.. Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study. Cancer Imaging. 2020;20 (1):72. doi: 10.1186/s40644-020-00351-w. PubMed PMID:33036660 PubMed Central PMC7547469.
5. Pöyhönen, A, Åkerla, J, Koskimäki, J, Tammela, TLJ, Auvinen, A. Seasonal changes in occurrence and severity of lower urinary tract symptoms-Tampere Aging Male Urologic Study (TAMUS). Low Urin Tract Symptoms. 2021;13 (2):216-223. doi: 10.1111/luts.12353. PubMed PMID:33034153 .
6. Woodcock, DJ, Riabchenko, E, Taavitsainen, S, Kankainen, M, Gundem, G, Brewer, DS et al.. Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy. Nat Commun. 2020;11 (1):5070. doi: 10.1038/s41467-020-18843-5. PubMed PMID:33033260 PubMed Central PMC7545111.
7. Bailey, MH, Meyerson, WU, Dursi, LJ, Wang, LB, Dong, G, Liang, WW et al.. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun. 2020;11 (1):4748. doi: 10.1038/s41467-020-18151-y. PubMed PMID:32958763 PubMed Central PMC7505971.
8. Li, CH, Prokopec, SD, Sun, RX, Yousif, F, Schmitz, N, PCAWG Tumour Subtypes and Clinical Translation et al.. Sex differences in oncogenic mutational processes. Nat Commun. 2020;11 (1):4330. doi: 10.1038/s41467-020-17359-2. PubMed PMID:32859912 PubMed Central PMC7455744.
9. Gundem, G, Van Loo, P, Kremeyer, B, Alexandrov, LB, Tubio, JMC, Papaemmanuil, E et al.. Author Correction: The evolutionary history of lethal metastatic prostate cancer. Nature. 2020;584 (7820):E18. doi: 10.1038/s41586-020-2581-5. PubMed PMID:32728210 .
10. Savolainen, K, Scaravilli, M, Ilvesmäki, A, Staff, S, Tolonen, T, Mäenpää, JU et al.. Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts. BMC Res Notes. 2020;13 (1):311. doi: 10.1186/s13104-020-05155-6. PubMed PMID:32611374 PubMed Central PMC7329467.
11. Siltari, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PLoS One. 2020;15 (6):e0234269. doi: 10.1371/journal.pone.0234269. PubMed PMID:32598349 PubMed Central PMC7323967.
12. Kohvakka, A, Sattari, M, Shcherban, A, Annala, M, Urbanucci, A, Kesseli, J et al.. AR and ERG drive the expression of prostate cancer specific long noncoding RNAs. Oncogene. 2020;39 (30):5241-5251. doi: 10.1038/s41388-020-1365-6. PubMed PMID:32555329 .
13. Karunamuni, RA, Huynh-Le, MP, Fan, CC, Eeles, RA, Easton, DF, Kote-Jarai, Z et al.. The effect of sample size on polygenic hazard models for prostate cancer. Eur J Hum Genet. 2020;28 (10):1467-1475. doi: 10.1038/s41431-020-0664-2. PubMed PMID:32514134 PubMed Central PMC7608255.
14. Talala, K, Heinävaara, S, Taari, K, Tammela, TLJ, Kujala, P, Stenman, UH et al.. Long-term health-related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer. Cancer Med. 2020;9 (15):5643-5654. doi: 10.1002/cam4.3181. PubMed PMID:32500650 PubMed Central PMC7402814.
15. Stuopelyte, K, Sabaliauskaite, R, Bakavicius, A, Haflidadóttir, BS, Visakorpi, T, Väänänen, RM et al.. Reply by Authors. J Urol. 2020;204 (1):77-78. doi: 10.1097/JU.0000000000000803.02. PubMed PMID:32343215 .
16. Stuopelyte, K, Sabaliauskaite, R, Bakavicius, A, Haflidadóttir, BS, Visakorpi, T, Väänänen, RM et al.. Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate. J Urol. 2020;204 (1):71-78. doi: 10.1097/JU.0000000000000803. PubMed PMID:32068491 PubMed Central PMC7301408.
17. PCAWG Transcriptome Core Group, Calabrese, C, Davidson, NR, Demircioğlu, D, Fonseca, NA, He, Y et al.. Genomic basis for RNA alterations in cancer. Nature. 2020;578 (7793):129-136. doi: 10.1038/s41586-020-1970-0. PubMed PMID:32025019 PubMed Central PMC7054216.
18. Alexandrov, LB, Kim, J, Haradhvala, NJ, Huang, MN, Tian Ng, AW, Wu, Y et al.. The repertoire of mutational signatures in human cancer. Nature. 2020;578 (7793):94-101. doi: 10.1038/s41586-020-1943-3. PubMed PMID:32025018 PubMed Central PMC7054213.
19. Rheinbay, E, Nielsen, MM, Abascal, F, Wala, JA, Shapira, O, Tiao, G et al.. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020;578 (7793):102-111. doi: 10.1038/s41586-020-1965-x. PubMed PMID:32025015 PubMed Central PMC7054214.
20. Gerstung, M, Jolly, C, Leshchiner, I, Dentro, SC, Gonzalez, S, Rosebrock, D et al.. The evolutionary history of 2,658 cancers. Nature. 2020;578 (7793):122-128. doi: 10.1038/s41586-019-1907-7. PubMed PMID:32025013 PubMed Central PMC7054212.
21. Li, Y, Roberts, ND, Wala, JA, Shapira, O, Schumacher, SE, Kumar, K et al.. Patterns of somatic structural variation in human cancer genomes. Nature. 2020;578 (7793):112-121. doi: 10.1038/s41586-019-1913-9. PubMed PMID:32025012 PubMed Central PMC7025897.
22. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature. 2020;578 (7793):82-93. doi: 10.1038/s41586-020-1969-6. PubMed PMID:32025007 PubMed Central PMC7025898.
23. Cortés-Ciriano, I, Lee, JJ, Xi, R, Jain, D, Jung, YL, Yang, L et al.. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. 2020;52 (3):331-341. doi: 10.1038/s41588-019-0576-7. PubMed PMID:32025003 PubMed Central PMC7058534.
24. Zapatka, M, Borozan, I, Brewer, DS, Iskar, M, Grundhoff, A, Alawi, M et al.. The landscape of viral associations in human cancers. Nat Genet. 2020;52 (3):320-330. doi: 10.1038/s41588-019-0558-9. PubMed PMID:32025001 PubMed Central PMC8076016.
25. Akdemir, KC, Le, VT, Chandran, S, Li, Y, Verhaak, RG, Beroukhim, R et al.. Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet. 2020;52 (3):294-305. doi: 10.1038/s41588-019-0564-y. PubMed PMID:32024999 PubMed Central PMC7058537.
26. Rodriguez-Martin, B, Alvarez, EG, Baez-Ortega, A, Zamora, J, Supek, F, Demeulemeester, J et al.. Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet. 2020;52 (3):306-319. doi: 10.1038/s41588-019-0562-0. PubMed PMID:32024998 PubMed Central PMC7058536.
27. Yuan, Y, Ju, YS, Kim, Y, Li, J, Wang, Y, Yoon, CJ et al.. Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet. 2020;52 (3):342-352. doi: 10.1038/s41588-019-0557-x. PubMed PMID:32024997 PubMed Central PMC7058535.
28. Carlevaro-Fita, J, Lanzós, A, Feuerbach, L, Hong, C, Mas-Ponte, D, Pedersen, JS et al.. Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol. 2020;3 (1):56. doi: 10.1038/s42003-019-0741-7. PubMed PMID:32024996 PubMed Central PMC7002399.
29. Yakneen, S, Waszak, SM, PCAWG Technical Working Group, Gertz, M, Korbel, JO, PCAWG Consortium et al.. Butler enables rapid cloud-based analysis of thousands of human genomes. Nat Biotechnol. 2020;38 (3):288-292. doi: 10.1038/s41587-019-0360-3. PubMed PMID:32024987 PubMed Central PMC7062635.
30. Reyna, MA, Haan, D, Paczkowska, M, Verbeke, LPC, Vazquez, M, Kahraman, A et al.. Pathway and network analysis of more than 2500 whole cancer genomes. Nat Commun. 2020;11 (1):729. doi: 10.1038/s41467-020-14367-0. PubMed PMID:32024854 PubMed Central PMC7002574.
31. Jiao, W, Atwal, G, Polak, P, Karlic, R, Cuppen, E, PCAWG Tumor Subtypes and Clinical Translation Working Group et al.. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun. 2020;11 (1):728. doi: 10.1038/s41467-019-13825-8. PubMed PMID:32024849 PubMed Central PMC7002586.
32. Paczkowska, M, Barenboim, J, Sintupisut, N, Fox, NS, Zhu, H, Abd-Rabbo, D et al.. Integrative pathway enrichment analysis of multivariate omics data. Nat Commun. 2020;11 (1):735. doi: 10.1038/s41467-019-13983-9. PubMed PMID:32024846 PubMed Central PMC7002665.
33. Cmero, M, Yuan, K, Ong, CS, Schröder, J, PCAWG Evolution and Heterogeneity Working Group, Corcoran, NM et al.. Inferring structural variant cancer cell fraction. Nat Commun. 2020;11 (1):730. doi: 10.1038/s41467-020-14351-8. PubMed PMID:32024845 PubMed Central PMC7002525.
34. Rubanova, Y, Shi, R, Harrigan, CF, Li, R, Wintersinger, J, Sahin, N et al.. Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nat Commun. 2020;11 (1):731. doi: 10.1038/s41467-020-14352-7. PubMed PMID:32024834 PubMed Central PMC7002414.
35. Zhang, Y, Chen, F, Fonseca, NA, He, Y, Fujita, M, Nakagawa, H et al.. High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. Nat Commun. 2020;11 (1):736. doi: 10.1038/s41467-019-13885-w. PubMed PMID:32024823 PubMed Central PMC7002524.
36. Bhandari, V, Li, CH, Bristow, RG, Boutros, PC, PCAWG Consortium. Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun. 2020;11 (1):737. doi: 10.1038/s41467-019-14052-x. PubMed PMID:32024819 PubMed Central PMC7002770.
37. Shuai, S, PCAWG Drivers and Functional Interpretation Working Group, Gallinger, S, Stein, LD, PCAWG Consortium. Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nat Commun. 2020;11 (1):734. doi: 10.1038/s41467-019-13929-1. PubMed PMID:32024818 PubMed Central PMC7002750.
38. Sieverling, L, Hong, C, Koser, SD, Ginsbach, P, Kleinheinz, K, Hutter, B et al.. Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun. 2020;11 (1):733. doi: 10.1038/s41467-019-13824-9. PubMed PMID:32024817 PubMed Central PMC7002710.
39. Granberg, KJ, Raita, A, Lehtinen, B, Tiihonen, AM, Kesseli, J, Annala, M et al.. Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors. Histol Histopathol. 2020;35 (7):673-680. doi: 10.14670/HH-18-180. PubMed PMID:31660579 .

Search PubMed

1. Eerola, SK, Santio, NM, Rinne, S, Kouvonen, P, Corthals, GL, Scaravilli, M et al.. Phosphorylation of NFATC1 at PIM1 target sites is essential for its ability to promote prostate cancer cell migration and invasion. Cell Commun Signal. 2019;17 (1):148. doi: 10.1186/s12964-019-0463-y. PubMed PMID:31730483 PubMed Central PMC6858710.
2. Booth, N, Rissanen, P, Tammela, TLJ, Kujala, P, Stenman, UH, Taari, K et al.. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data. PLoS One. 2019;14 (11):e0224479. doi: 10.1371/journal.pone.0224479. PubMed PMID:31689326 PubMed Central PMC6830755.
3. Granberg, KJ, Raita, A, Lehtinen, B, Tiihonen, AM, Kesseli, J, Annala, M et al.. Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors. Histol Histopathol. 2020;35 (7):673-680. doi: 10.14670/HH-18-180. PubMed PMID:31660579 .
4. Santala, EEE, Kotsar, A, Veitonmäki, T, Tammela, TLJ, Murtola, TJ. Risk of urothelial cancer death among people using antihypertensive drugs-a cohort study from Finland. Scand J Urol. 2019;53 (4):185-192. doi: 10.1080/21681805.2019.1634147. PubMed PMID:31250699 .
5. Kinnunen, PTT, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer. Cancer Causes Control. 2019;30 (8):877-888. doi: 10.1007/s10552-019-01195-x. PubMed PMID:31209595 .
6. Carlsson, SV, Månsson, M, Moss, S, Kwiatkowski, M, Recker, F, Tammela, TLJ et al.. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?. Eur Urol. 2019;75 (6):1015-1022. doi: 10.1016/j.eururo.2019.03.010. PubMed PMID:30928162 PubMed Central PMC7526685.
7. Hugosson, J, Roobol, MJ, Månsson, M, Tammela, TLJ, Zappa, M, Nelen, V et al.. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol. 2019;76 (1):43-51. doi: 10.1016/j.eururo.2019.02.009. PubMed PMID:30824296 PubMed Central PMC7513694.
8. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2019;22 (3):483-490. doi: 10.1038/s41391-019-0129-2. PubMed PMID:30696944 .
9. Murtola, TJ, Sälli, SM, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer. Prostate Cancer Prostatic Dis. 2019;22 (3):453-460. doi: 10.1038/s41391-018-0123-0. PubMed PMID:30679762 .
10. Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X et al.. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2019;10 (1):382. doi: 10.1038/s41467-019-08293-z. PubMed PMID:30655571 PubMed Central PMC6336778.
11. Schumacher, FR, Olama, AAA, Berndt, SI, Benlloch, S, Ahmed, M, Saunders, EJ et al.. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2019;51 (2):363. doi: 10.1038/s41588-018-0330-6. PubMed PMID:30622367 .
12. Åkerla, J, Pesonen, JS, Pöyhönen, A, Häkkinen, J, Koskimäki, J, Huhtala, H et al.. Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men. Prostate Cancer Prostatic Dis. 2019;22 (2):317-323. doi: 10.1038/s41391-018-0108-z. PubMed PMID:30410016 .
13. Li-Sheng Chen, S, Ching-Yuan Fann, J, Sipeky, C, Yang, TK, Yueh-Hsia Chiu, S, Ming-Fang Yen, A et al.. Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen. J Urol. 2019;201 (3):486-495. doi: 10.1016/j.juro.2018.10.015. PubMed PMID:30366021 .
14. Pakarainen, T, Nevalainen, J, Talala, K, Taari, K, Raitanen, J, Kujala, P et al.. The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). Clin Cancer Res. 2019;25 (2):839-843. doi: 10.1158/1078-0432.CCR-18-1807. PubMed PMID:30322875 .
15. Murtola, TJ, Kasurinen, TVJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. Prostate Cancer Prostatic Dis. 2019;22 (1):66-76. doi: 10.1038/s41391-018-0087-0. PubMed PMID:30214034 .
16. Assel, M, Sjöblom, L, Murtola, TJ, Talala, K, Kujala, P, Stenman, UH et al.. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol Focus. 2019;5 (4):561-567. doi: 10.1016/j.euf.2017.11.002. PubMed PMID:29137895 PubMed Central PMC5948115.

Search PubMed

1. Siltari, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort. Scand J Urol. 2018;52 (5-6):321-327. doi: 10.1080/21681805.2018.1559882. PubMed PMID:30698056 .
2. Schiewer, MJ, Mandigo, AC, Gordon, N, Huang, F, Gaur, S, de Leeuw, R et al.. PARP-1 regulates DNA repair factor availability. EMBO Mol Med. 2018;10 (12):. doi: 10.15252/emmm.201708816. PubMed PMID:30467127 PubMed Central PMC6284389.
3. Åkerla, J, Pesonen, JS, Pöyhönen, A, Häkkinen, J, Koskimäki, J, Huhtala, H et al.. Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men. Prostate Cancer Prostatic Dis. 2019;22 (2):317-323. doi: 10.1038/s41391-018-0108-z. PubMed PMID:30410016 .
4. Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X et al.. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2018;9 (1):4616. doi: 10.1038/s41467-018-06863-1. PubMed PMID:30397198 PubMed Central PMC6218483.
5. Pöyhönen, A, Åkerla, J, Häkkinen, JT, Koskimäki, J, Tammela, TLJ, Auvinen, A et al.. Severity and bother of lower urinary tract symptoms among men aged 30-80 years: Tampere Ageing Male Urological Study (TAMUS). Scand J Urol. 2018;52 (4):296-301. doi: 10.1080/21681805.2018.1505944. PubMed PMID:30382800 .
6. Rantaniemi, L, Tammela, TLJ, Kujala, P, Murtola, TJ. Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy. Scand J Urol. 2018;52 (4):269-276. doi: 10.1080/21681805.2018.1492967. PubMed PMID:30362865 .
7. Pakarainen, T, Nevalainen, J, Talala, K, Taari, K, Raitanen, J, Kujala, P et al.. The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). Clin Cancer Res. 2019;25 (2):839-843. doi: 10.1158/1078-0432.CCR-18-1807. PubMed PMID:30322875 .
8. Latonen, L, Nykter, M, Visakorpi, T. Proteomics of prostate cancer – revealing how cancer cells master their messy genomes. Oncoscience. 2018;5 (7-8):216-217. doi: 10.18632/oncoscience.453. PubMed PMID:30234142 PubMed Central PMC6142899.
9. Murtola, TJ, Kasurinen, TVJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. Prostate Cancer Prostatic Dis. 2019;22 (1):66-76. doi: 10.1038/s41391-018-0087-0. PubMed PMID:30214034 .
10. Sipeky, C, Gao, P, Zhang, Q, Wang, L, Ettala, O, Talala, KM et al.. Synergistic Interaction of and Predisposes to Aggressive Prostate Cancer. Clin Cancer Res. 2018;24 (24):6265-6276. doi: 10.1158/1078-0432.CCR-18-0444. PubMed PMID:30181389 PubMed Central PMC6719560.
11. Veskimäe, K, Scaravilli, M, Niininen, W, Karvonen, H, Jaatinen, S, Nykter, M et al.. Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies. Transl Oncol. 2018;11 (5):1160-1170. doi: 10.1016/j.tranon.2018.07.010. PubMed PMID:30056367 PubMed Central PMC6079561.
12. Gao, P, Xia, JH, Sipeky, C, Dong, XM, Zhang, Q, Yang, Y et al.. Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus. Cell. 2018;174 (3):576-589.e18. doi: 10.1016/j.cell.2018.06.003. PubMed PMID:30033361 PubMed Central PMC6091222.
13. Murtola, TJ, Syvälä, H, Tolonen, T, Helminen, M, Riikonen, J, Koskimäki, J et al.. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol. 2018;74 (6):697-701. doi: 10.1016/j.eururo.2018.06.037. PubMed PMID:30031572 .
14. Kallio, HML, Hieta, R, Latonen, L, Brofeldt, A, Annala, M, Kivinummi, K et al.. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. Br J Cancer. 2018;119 (3):347-356. doi: 10.1038/s41416-018-0172-0. PubMed PMID:29988112 PubMed Central PMC6070921.
15. Kaapu, KJ, Rantaniemi, L, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men. Sci Rep. 2018;8 (1):10308. doi: 10.1038/s41598-018-28541-4. PubMed PMID:29985440 PubMed Central PMC6037774.
16. Dadaev, T, Saunders, EJ, Newcombe, PJ, Anokian, E, Leongamornlert, DA, Brook, MN et al.. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat Commun. 2018;9 (1):2256. doi: 10.1038/s41467-018-04109-8. PubMed PMID:29892050 PubMed Central PMC5995836.
17. Schumacher, FR, Al Olama, AA, Berndt, SI, Benlloch, S, Ahmed, M, Saunders, EJ et al.. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50 (7):928-936. doi: 10.1038/s41588-018-0142-8. PubMed PMID:29892016 PubMed Central PMC6568012.
18. Tolonen, TT, Riikonen, J, Tammela, TLJ, Koivusalo, L, Haapasalo, H, Kujala, P et al.. Extraprostatic extension (pT3a) in prostate biopsy is an under-recognized feature indicating high risk disease. Ann Diagn Pathol. 2018;35 :80-84. doi: 10.1016/j.anndiagpath.2018.06.001. PubMed PMID:29886397 .
19. Mäkelä, VJ, Kotsar, A, Tammela, TLJ, Murtola, TJ. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors. J Urol. 2018;200 (4):743-748. doi: 10.1016/j.juro.2018.04.082. PubMed PMID:29730200 .
20. Sainio, M, Visakorpi, T, Tolonen, T, Ilvesaro, J, Bova, GS. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer. Pathol Res Pract. 2018;214 (6):848-856. doi: 10.1016/j.prp.2018.04.015. PubMed PMID:29728311 .
21. Kartasalo, K, Latonen, L, Vihinen, J, Visakorpi, T, Nykter, M, Ruusuvuori, P et al.. Comparative analysis of tissue reconstruction algorithms for 3D histology. Bioinformatics. 2018;34 (17):3013-3021. doi: 10.1093/bioinformatics/bty210. PubMed PMID:29684099 PubMed Central PMC6129300.
22. Wedge, DC, Gundem, G, Mitchell, T, Woodcock, DJ, Martincorena, I, Ghori, M et al.. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet. 2018;50 (5):682-692. doi: 10.1038/s41588-018-0086-z. PubMed PMID:29662167 PubMed Central PMC6372064.
23. Latonen, L, Afyounian, E, Jylhä, A, Nättinen, J, Aapola, U, Annala, M et al.. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat Commun. 2018;9 (1):1176. doi: 10.1038/s41467-018-03573-6. PubMed PMID:29563510 PubMed Central PMC5862881.
24. Booth, N, Rissanen, P, Tammela, TLJ, Taari, K, Talala, K, Auvinen, A et al.. Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data. Eur J Cancer. 2018;93 :108-118. doi: 10.1016/j.ejca.2018.01.111. PubMed PMID:29501976 .
25. Claessens, F, Visakorpi, T. Endocrinology of prostate cancer. Mol Cell Endocrinol. 2018;462 (Pt A):1-2. doi: 10.1016/j.mce.2018.01.005. PubMed PMID:29463415 .
26. Ahlgren, GM, Flodgren, P, Tammela, TLJ, Kellokumpu-Lehtinen, P, Borre, M, Angelsen, A et al.. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. Eur Urol. 2018;73 (6):870-876. doi: 10.1016/j.eururo.2018.01.012. PubMed PMID:29395502 .
27. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2018;21 (3):373-378. doi: 10.1038/s41391-017-0031-8. PubMed PMID:29273728 .
28. McNair, C, Xu, K, Mandigo, AC, Benelli, M, Leiby, B, Rodrigues, D et al.. Differential impact of RB status on E2F1 reprogramming in human cancer. J Clin Invest. 2018;128 (1):341-358. doi: 10.1172/JCI93566. PubMed PMID:29202480 PubMed Central PMC5749518.
29. Högnäs, G, Kivinummi, K, Kallio, HML, Hieta, R, Ruusuvuori, P, Koskenalho, A et al.. Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues. Am J Surg Pathol. 2018;42 (1):103-115. doi: 10.1097/PAS.0000000000000961. PubMed PMID:28984675 .
30. Murtola, TJ, Vettenranta, AM, Talala, K, Taari, K, Stenman, UH, Tammela, TLJ et al.. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. Eur Urol Focus. 2018;4 (6):851-857. doi: 10.1016/j.euf.2017.03.005. PubMed PMID:28753870 .

Search PubMed